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Summary 
Parkinson’s disease (PD) is a neurodegenerative disorder, marked by 
the selective degeneration of dopaminergic neurons in the nigrostriatal 
pathway. Several lines of evidence indicate that mitochondrial dysfunction 
contributes to its etiology. Other studies have suggested that alterations in 
sterol homeostasis correlate with increased risk for PD. Whether these 
observations are functionally related is, however, unknown. In this study, I 
used a toxin-induced mouse model of PD and measured levels of nine sterol 
intermediates. I found that lanosterol is significantly (~50%) and specifically 
reduced in the nigrostriatal regions of MPTP-treated mice, indicative of 
altered lanosterol metabolism during PD pathogenesis. Remarkably, 
exogenous addition of lanosterol rescued dopaminergic neurons from MPP+-
induced cell death in culture. Furthermore, there is a marked redistribution of 
lanosterol synthase (LSS) from the endoplasmic reticulum (ER) to 
mitochondria in dopaminergic neurons exposed to MPP+, suggesting of that 
lanosterol might exert its survival effect by regulating mitochondria function. 
Consistent with this model, I find that lanosterol induces mild depolarization 
of mitochondria and promotes autophagy. Collectively, these results highlight 
a novel sterol-based neuroprotective mechanism with direct relevance to PD. 
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Introduction 
Parkinson’s Disease (PD) is a movement disorder marked by selective 
degeneration of dopaminergic neurons in the nigrostriatum pathway (Dauer 
and Przedborski, 2003). It affects about 1% of the population over 60 years 
old and 4% of people over 80 years old. Named after the clinician who first 
described the disease in 1817, James Parkinson, this is currently the second 
most common age-related neurodegenerative disorder (Elbaz and Moisan, 
2008).  
The clinical characterization of the disease, started about half a century 
ago, is extremely accurate. Among experienced clinicians, PD is diagnosed 
with a 98.5% accuracy (de Lau and Breteler, 2006), compared to about 83% 
for Alzheimer’s disease (Lim et al., 1999). Most patients with PD exhibit 
numerous deficits in movement with obvious symptoms such as: rigidity or 
stiffness of limbs and/or neck, tremor, bradykinesia, and reduction of 
movement. Other less apparent symptoms include depression, dementia or 
confusion, uncontrolled drooling, speech impairment, swallowing difficulty, 
and constipation.  
The main clinical features of PD are caused by the selective loss of 
dopaminergic neurons in the nigrostriatal pathway, which is also a hallmark of 
the disease. However, it is important to note that neuronal cell deaths are also 
detected in other regions of the brain such as cerebellum and cortex (Braak et 
al., 2003). Clearly, the most severely affected region is the nigrostriatal 
pathway (Fig 1), which regulates fine voluntary movements. Thus, the main 
motor deficits in PD patients are most likely attributed to this pathway, while 
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the other less common and non-motor symptoms such as confusion and 
dementia are most likely due to impairments in other brain regions.  
In a healthy nigrostriatal circuit (Fig 1A), dopaminergic neurons from 
the substantia nigra par compacta (SNpc) send both excitatory and inhibitory 
signals to two types of GABAergic neurons in the striatum, which have either 
receptor of D1 (dopamine receptor subtype 1) or D2 (dopamine receptor 
subtype 2) respectively. GABAergic neurons with D1 receptors form the 
direct pathway, whereas neurons with D2 receptors form the indirect pathway.  
These two pathways link the striatum to the cortex via the thalamus and 
subthalmic nucleus. In PD, the loss of dopaminergic input from the SNpc 
typically leads to overactivity in the indirect output and underactivity of the 
direct output of the nigrostriatal circuit (Fig 1B). This results in a reduction of 
movement due to reduced glutamergic output from the thalamus to the motor 
cortex.  
The overactive indirect pathway and the underactive direct pathway 
have long been proposed to be the cause of motor deficits in Parkinsonism 
(Bergman et al., 1990). As such, a number of deep-brain stimulation and 
surgical procedures are aimed at reducing this indirect pathway. However, 
until recently, there has been no direct experimental evidence to suggest that 
this is the case. Consistent with the classical model proposed, in 2010, a 
seminal paper by Anotol Kreitzer’s group in collaboration with Karl 
Deisseroth (one of the pioneers of optogenetic techniques), demonstrated that 
the activation of GABAergic neurons from the striatum with D1 receptor 
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(direct pathway) reduce freezing and increase locomotion in a mouse model 
for PD (Kravitz et al., 2010).   
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Figure 1: Graphical drawing of sagittal plane of a rodent brain, left represents anterior and right 
represents posterior. (A) In a healthy state, dopaminergic neurons in the substantial nigra par compacta 
(SNpc) send excitatory and inhibitory signals to two classes of GABAergic neurons of the caudate 
putamen (striatum), consisting of D1 and D2 receptors respectively. In the direct pathway, D1 
GABAergic neurons synapse onto GABAergic neurons of the globus pallidus internal segment (GPi). 
GPi GABAergic neurons synapse onto gluatmergic neurons of the thalamus (THAL), sending signal to 
the motor cortex. In the indirect pathway, D2 GABAergic neurons synapse onto GABAergic neurons of 
the globus pallidus external segment (GPe). GPe GABAergic neurons synapse onto glutamergic neurons 
of the subthalmic nucleus (STN). From STN, glutamergic neurons synapse onto GPi GABAerigc 
neurons. The balance between this direct and indirect pathway results in fine motor coordination such as 
speech. (B) In PD, upon the loss of dopaminergic neurons, D1 (direct) pathway is less active wheras D2 
(indirect) is hyperactive. The final result is an over-inhibition of thalamic neurons, reducing glutamergic 
synapses from the thalamus to motor cortex. Movement deficits are thus in patients with defects in the 
nigrostriatal circuit.  
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From the genetic level, in 1997, the first gene mutation identified to 
cause an inherited form of PD was alpha-synuclein (PARK1/4). Since then, 
numerous genes, such as PINK1 (PARK6), LRRK2 (PARK8), DJ1 (PARK7), 
Parkin (PARK5), and other loci (list in Table 1), have been identified to be 
involved in familial PD (Schapira, 2008). These disease-associated mutations 
represent only 5-10% of all PD cases; the remaining 90-95% have currently 
unknown causes (Lesage and Brice, 2009). Though genetic causes of 
Parkinsonism represent the minority of total incidences, they have been 
important to the PD field in deciphering the events of pathogenesis.  
For example, taking advantage of the disease-related mutations, there 
are now many transgenic model organisms including mice (see Table 1), 
worm, yeast, and flies. All of these models have been instrumental in 
uncovering the molecular and cellular events that lead to cell death. Despite 
the importance of transgenic models, it is important to note that none of the 
genetic models expressing familial PD mutations are well established and 
could recapitulate the hallmark of PD such as the selective loss of 
dopaminergic neurons. The notable exceptions, such as overexpression of α-
synuclein and Lrrk2, are highly controversial. For example, in the case of α-
synuclein, overexpression of wild type human form of α-synuclein also 
induces a selective loss of dopaminergic neurons, suggesting that the observed 
phenotype is an overexpression artefact. For Lrrk2, while the R1441G 
transgene induces selective loss of dopaminergic neurons in the SNpc, the 
R1441C does not (Li et al., 2009). In a recent paper, mice overexpressing the 
G2019S mutation of Lrrk2 showed a selective loss of dopaminergic neurons in 
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the SNpc. However, the authors were extremely cautious of the results, since 
this is unique to a specific mouse line as the same mutation in a different line 
did not recapitulate this (Ramonet et al., 2011).  
In the same line of thinking, other groups have taken a different 
approach trying to elucidate the selective vulnerability of dopaminergic 
neurons. It is well known that in PD, dopaminergic neurons have degenerated 
in the SNpc while the adjacent dopaminergic neuron of the VTA remain. Thus 
by comparing gene-array expression profiles in dopaminergic neurons in these 
two regions, one could theoretically find pathways or genes unique to 
dopaminergic neurons of the SNpc. In a few array studies, the results 
suggested that different expression of transcription factors may explain the 
selective vulnerability of dopaminergic neurons (Chung et al., 2005; Greene et 
al., 2005; Yao et al., 2005). However, it is also not clear how these array data 
fit with the known PD- linked mutations or what risk factors could cause such 
differences in expression of these identified transcription factors.  
The current consensus is that PD is a multifactorial disease, whereby 
both extrinsic factors, such as exposure to environmental toxins, and intrinsic 
factors, such as genetic background, are important for pathogenesis (Ross and 
Smith, 2007). More importantly, there is a growing list of components 
associated with PD’s etiology such as: oxidative stress, ER protein misfolding, 
mitochondria dysfunction, transcription factors changes, epigenetic changes, 
calcium toxicity, and cholesterol misregulation. It is not known if all of the 
above are related or independent factors for the disease’s progression. Among 
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this list, the evidence implicating the involvement of impaired mitochondrial 
functions in PD appears to be the most substantial.  
As mentioned, the genetic linkage represent only 5-10% of all PD 
occurrences (Lesage and Brice, 2009). Yet, in this list of rare genetic PD 
cases, many genes point towards mitochondrial dysfunction (see compiled list 
in Table 1, (Dauer and Przedborski, 2003; Elbaz and Moisan, 2008; Lesage 
and Brice, 2009; Ross and Smith, 2007; Schapira, 2008; Schon and 
Przedborski, 2011)). A number of these genes, such as PINK1, DJ-1, and 
HTRA2, localize to the mitochondria, and have been shown to control 
mitophagy during oxidative stress (Cookson, 2010). Another gene involved in 
PD, Parkin, interacts with Parkin-interacting substrates (PARIS), which in turn 
represses PGC-1α expression. Repression of PGC-1α reduces mitochondria 
bioenergetics (Shin et al., 2011). Parkin also interacts with PINK1, and 
together they play important roles in mitophagy (Matsuda et al., 2010; 
Narendra et al., 2008; Narendra et al., 2010).  In patients with idiopathic PD, 
brain mitochondrial complex I catalytic activity is compromised (Keeney et 
al., 2006). Furthermore, a number of environmental toxins that directly affect 
mitochondrial function induce Parkinsonism. For example, in the French 
Indian island of Guadeloupe, a typical Parkinsonism has been closely 
associated with the regular consumption of soursop, a tropical plant containing 
the complex I inhibitor, annonacin (Schapira, 2008; Schapira, 2010). Perhaps 
the best example of toxin-induced PD is MPTP (or its active metabolite 
MPP+), which is the main contaminant found in the illegally manufactured 
opioid drugs. MPP+ selectively enters into dopaminergic neurons via the 
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dopamine transporter (DAT), inhibits complex I of the mitochondria, and 
recapitulates PD’s clinical symptoms (Watanabe et al., 2005). 
Because MPTP/MPP+ toxicity emulates PD symptoms, it has been 
widely used in animal and cellular models to study neuronal cell death and to 
screen for neuroprotective agents. Of the neuroprotective metabolites 
identified, many are found in mitochondria, including L-carnitine, creatine, 
and coenzyme Q10 (CoQ) (Virmani et al., 2005). Among these metabolites, 
CoQ is a class of lipid-based electron carrier found predominately in the 
mitochondria. In some cohorts of patients with PD, administering CoQ is 
beneficial, but its efficacy has yet to be determined (Muller et al., 2003; Shults 
et al., 2002; Spindler et al., 2009). In MPTP rodent and primate animal model, 
the supplement of CoQ is partially protective by inducing “mild” uncoupling 
in nigral neurons (Horvath et al., 2003). However, other than CoQ, no other 
classes of lipids have been shown to be important in modulating mitochondrial 
function and improving dopaminergic neuronal survival. Consistent with this 
model, uncoupling proteins (UCPs) are protective in the MPTP model of PD 
(Andrews et al., 2005; Conti et al., 2005), and their expression is down 
regulated in mice lacking DJ-1, a gene linked to early onset of PD (Guzman et 
al., 2010).  
While the evidence implicating mitochondria in PD is substantial, the 
evidence showing the involvement of lipid misregulation is relatively weak. 
Even though about fifty percent of the brain’s dry weight is lipid, 
neuroscientists still have a limited explanation for this observation (Piomelli et 
al., 2007). Perhaps the simplest explanation for a high lipid composition is due 
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to white matter, which is largely composed of myelin. However, emerging 
evidence now shows that beyond acting as insulators, lipids also play 
important regulatory roles in signalling (Piomelli et al., 2007). Due to the high 
diversity in structural, biochemical and biophysical properties of lipid 
molecules (see chapter 1, Fig 2), they participate in a range of brain function 
including development, synaptic vesicle cycle, axonal cargo trafficking, and 
even in disease pathogenesis (Buccoliero and Futerman, 2003; Di Paolo and 
De Camilli, 2006; Vance et al., 2006).  
In the context of PD, there is some evidence for the involvement of 
lipids. In clinical studies, low-density lipoprotein cholesterol (LDL-C) has 
been associated with higher risk of PD (Huang et al., 2008; Huang et al., 
2007), and higher serum levels of total cholesterol were associated with a 
significantly decreased risk of PD (de Lau et al., 2006). Yet, these might not 
reflect brain cholesterol levels as cholesterol in the brain is synthesized 
independently of the rest of the body. While oxidized cholesterol has been 
shown to accelerate α-synucleinopathy – the major component of Lewy 
bodies – (Koob et al., ; Liu et al., ; Rantham Prabhakara et al., 2008), these 
studies were done mostly in vitro. In the brains of post-mortem PD patients, 
elevated levels of polyunsaturated fatty acids (PUFA) were detected (Sharon 
et al., 2003), but this represents cortices rather than affected brain regions. 
Clinically, there have been some reports linking Gaucher disease (a defect in 
glucocerebrosidase activitiy) to Parkinsonism (Aharon-Peretz et al., 2004; 
Zimran et al., 2005). Yet, it is still unclear how lipid metabolism and 
mitochondria function relates to PD disease progression or dopaminergic 
Lynette Lim Lanosterol is a survival factor for dopaminergic neuron 
Page 10 
neuronal degeneration. Whether misregulation in lipid metabolism and 
mitochondria dysfunction collaborate together in the selective cell death of 
dopaminergic neuron, or whether they are simply two independent factors 
remains to be elucidated. 
Despite the lack of strong evidence for the involvement of lipids in PD, 
some findings mentioned above have been translated into treatments, though 
they are not entirely successful. The lipid-based therapies currently being 
evaluated in clinical trials for PD include polyunsaturated fatty acids (PUFA), 
such as fish-oils or docodehexanoic acid (DHA), and statins – classes of sterol 
lowering drugs. Fish oil appears to ameliorate depressive symptoms that are 
common among PD patients (da Silva et al., 2008), but the mechanism of 
action is unclear. Sterol-lowering drugs results have been conflicting as some 
studies reported a protective effect while many others see no effects, rendering 
no definite conclusion to be made (see review (Becker and Meier, 2009).  
This work begins with the goal to (i) screen for lipid levels in brain 
that can contribute to the pathogenesis of PD, (ii) modify the lipids levels of 
dopaminergic neurons to assess their survival, and (iii) identify the mechanism 
of action of lipids metabolites in promoting cellular survival. This thesis is 
divided into various chapters that detail the different types of experimental 
procedures and results. I will now give a brief summary of each chapter.  
 
Chapter 1: In silico analysis of the classes of lipids that could be particularly 
important to dopaminergic neurons. This in silico screen led to the 
identification of sterol metabolism as a candidate pathway. Upon measuring 
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nine precursors of cholesterol in the brains of mice treated with MPTP, a drug 
inhibiting complex I of the mitochondria respiratory chain and mimicking PD, 
levels of lanosterol, the first cyclic sterol, were found to be significantly 
reduced (chapter 1).  
 
Chapter 2: To elucidate the role of lanosterol, I developed a modified method 
of culturing primary dopaminergic neurons. Upon establishing this method, I 
found that in ventral midbrain cultures, exogenous lanosterol rescues 
dopaminergic neurons from MPP+-induced cell death. In hippocampal 
cultures, lanosterol, along with cholesterol, induces neurite outgrowth. 
Lanosterol was identified as a survival factor in primary dopaminergic 
neuronal cultures.  
 
Chapter 3: To determine if other metabolites alter upon addition of sterols, I 
performed GC-MS analysis on cultured neurons. Cell treated with lanosterol 
have marked increased levels of lanosterol, while other sterols appeared 
unchanged. Furthermore, ubiquinone levels did not change in neuronal 
cultures treated with sterols.  
 
Chapter 4: To decipher the mechanism of lanosterol’s survival effect, I 
evaluated a number of survival pathways that have been reported to change in 
PD or animal model of PD. Furthermore, I also checked the levels and the 
localization of lanosterol synthase (LSS) in dopaminergic neurons. Upon 
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toxin-induced stress, we observed that LSS redistributed from ER to 
mitochondria.  
 
Chapter 5: To understand the role of LSS translocation from ER to 
mitochondria, I evaluated the role of lanosterol in modulating mitochondrial 
functions. I developed a live-imaging technique to monitor mitochondrial 
membrane potential. In this assay, I found that lanosterol induces “mild” 
uncoupling of the mitochondria, a mechanism that has been shown to be 
neuroprotective in several PD and neurodegeneration models. Finally, 
autophagy was increased upon lanosterol treatment. Collectively, these results 
point to lanosterol as a modulator of neuronal mitochondrial physiology and 
identify its unique role in the context of PD pathogenesis. 
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Mouse model & evidence of 
nigrostriatal compromises refs 





Knockout has fewer dock synaptic vesicles; 
overexpression of disease associated mutant 




Larsen et al., 2009; 
Lo Bianco et al., 
2002) 
PARK2 recessive 20s Parkin cytosol mitophagy 
Knockout does not display nigrostriatal 
degeneration; truncated mutation driven by 
DAT promoter has loss of dopaminergic 
neurons at 16 months. 
(Frank-Cannon et 
al., 2008; Lu et al., 
2009) 
PARK3 dominant 60s 2p13     
PARK5 dominant 50s UCHL1 cytosol ? 
Knockout has axonopathy but no selective 
loss of dopaminergic neurons. 
(Dauer and 
Przedborski, 2003)  
PARK6 recessive 30s PINK1 mito mitophagy 
conditional RNAi has no loss of 
dopaminergic neuron. (Zhou et al., 2007) 
PARK7 recessive 30s DJ-1 cytosol/mito 
mitophagy & oxidative 
stress 
Disease associated mutant has accumulation 
of mitochondria; knockout has defects in 




Guzman et al., 
2010) 
PARK8 dominant variable LRRK2 cytosol 
associates with mito outer 
membrane 
R1441G transgenic has loss of dopaminergic 
neurons; but R1441C has no loss of 
dopaminergic neurons; G2019S transgenic 
has specific loss of dopaminergic neurons but 
this is line dependent. 
(Li et al., 2009; 
Ramonet et al., 
2011) 
PARK9 recessive variable ATP13A2 membrane ? No model yet.  
PARK10 recessive variable 1p32     
PARK11 dominant variable GIGYF2 ER/ Golgi 
enhances mito ERK1/2 
activation GIgYF2 (+/-) has motor dysfunction. 
(Giovannone et al., 
2009) 
PARK12 ? ? Xq21-q25     
PARK13 ? ? HTRA2 mito apoptosis 
Abnormality of lower motor neuron function, 
also mutated in motor neuron disease. (Jones et al., 1993) 
PARK14 ? ? PLA2G6 ER associates with MAM 
Point mutation (loss of function) has severe 
motor dysfunction, model of infantile 
neuroaxonal dystrophy (Wada et al., 2009) 
PARK15 recessive ? FBXO7 nucleus  ? No model yet (Zhao et al., 2011) 
PARK16 ? ? 1q32      
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Chapter 1: Identification of a lipid metabolic pathway with potential 
relevance for dopaminergic neurons 
Introduction: Rational for in silico analyses  
 
One of the most puzzling questions in PD is why do dopaminergic 
neurons in the nigrostriatum pathway selectively degenerate? This hallmark 
feature of the disease has prompted various groups to conduct array studies 
comparing gene profiles of dopaminergic neurons in the SNpc to the ventral 
tegmental area (VTA). Yet, none of these array studies have conclusively 
mapped out a pathway that could explain the vulnerability of dopaminergic 
neurons. 
Instead of comparing genetic profile changes of dopaminergic neurons 
in these two regions of the brain, we sought to look at groups of genes or 
pathways that are differentially expressed among various classes of neurons. 
We reasoned that such genes would be the key to explain the selective 
vulnerability of dopaminergic neurons observed in PD.  In line with our logic, 
we employed the data generated from a study by Sugino et al., (2006). This 
array study took on an impressive and comprehensive task to molecularly 
characterize twelve major neuronal classes in the adult mouse forebrain. Their 
goal was to provide a molecular taxonomy for various subtypes of neurons. 
Sugino and colleagues also pointed out in their results that there is a large 
heterogeneity in gene expression among neurons. These differentially 
expressed genes (within the 12 populations of neurons investigated) fall into 
processes associated with cell-cell communication, synaptic vesicle dynamics, 
lipid binding, and lipid metabolism (Sugino et al., 2006). 
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Since different classes of neurons differ in their lipid metabolism 
genes, it is conceivable that vulnerabilities of dopaminegic neurons could be 
attributed to their lipid metabolic pathways. While lipids have been 
traditionally downplayed as membrane structural blocks and energy storage 
molecules, their functional importance is slowly gaining more attention. 
Furthermore, since lipids are highly diverse classes of molecules (Fahy et al., 
2007), they are multifunctional in nature. Biologically, their roles include 
serving as signalling molecules and essential co-factors, governing functions 
as diverse as endo and extocytosis, survival, growth factor responses, and even 
apoptosis (Buccoliero and Futerman, 2003; Di Paolo and De Camilli, 2006; 
Vance et al., 2006). It is thus conceivable that part of the vulnerability of 
dopaminergic neurons lies in their unique lipid metabolic needs.  
In line with this hypothesis, genes involved in PD, despite their 
functions, should also be highly differentially expressed among various 
classes of neurons. As a first proof of principle to this hypothesis, we gathered 
a list of genes reported to be involved in familial forms of PD (Table 2) and 
checked if they are differentially expressed among the twelve classes of 
neurons from the microarray data of Sugino et al., (2006). Out of the 19 genes 
in this list, fourteen (~73%) were highly differentially expressed (p-values, 
Table 2).  
However, it is important to note that none of these 12 classes of 
neurons used in this array study are dopaminergic. Thus, a second proof of 
concept consists of assessing if genes differentially expressed between 
dopaminergic neurons from the SNpc and VTA. These genes should also be 
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differentially expressed genes according to the Sugino et al. paper. To our 
knowledge, three groups have compared gene expression of dopaminergic 
neurons in SNpc and compared to dopaminergic neurons in the VTA (Chung 
et al., 2005; Greene et al., 2005; Yao et al., 2005). Greene et al (2005), found 
141 transcripts to be differentially expressed in rats. Chung et al., (2005), used 
mice and listed 125 transcripts with 2 fold differences in expression between 
the 2 types of dopaminergic neurons with 9 unknown genes. The results from 
Yao et al. (2005) were difficult to interpret due to some contamination with 
glia markers. Between the other two studies, Greene et al. and Chung et al., 
116 transcripts overlapped. Thus, we cross-referenced these 116 transcripts to 
Sugino et al. (2006) study, and found that 103/116 (88%) carried a p-value of 
<0.001 (Data not shown). 
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Table 2: A list of genes implicated in PD and corresponding p-values 
 
Gene symbol Name *p-value 
Snca alpha-synuclein 2.11E-17 
Lrrk2 leucine-rich repeat kinase 2 1.72E-12 
Sncg synuclein, gamma 2.67E-12 
Mapt microtubule-associated protein tau 6.13E-11 
Ube2g2 ubiquitin-conjugating enzyme E2G 2 6.12E-09 
Park7 
Parkinson disease (autosomal 
recessive, early onset) 7/ DJ-1 6.12E-09 
Sncaip alpha-synuclein interacting protein 2.78E-06 
Uchl1 
ubiquitin carboxy-terminal hydrolase 
L1 7.17E-06 
Comt catechol-O-methyltransferase 1.28E-05 
Sncb synuclein, beta 2.02E-05 
#Th tyrosine hydroxylase 2.41E-05 
Gpr37 G protein-coupled receptor 37 6.04E-05 
Pink1 PTEN induced putative kinase 1 2.93E-04 
Ube2l3 ubiquitin-conjugating enzyme E2L 3 4.57E-04 
Ube2j2 
ubiquitin-conjugating enzyme E2, J2 
homolog (yeast) 7.54E-03 
Ubb ubiquitin B 1.71E-02 
Park2 parkin (E3 ligase) 2.29E-02 
Ube2l6 ubiquitin-conjugating enzyme E2L 6 2.30E-02 
Ube1x ubiquitin-activating enzyme E1, Chr X 1.67E-01 
 
  
Material and Methods: In silico establishment of two-criteria system and 
MPTP mouse model 
In silico analyses 
I began to screen for lipid metabolic pathways. Lipids, as mentioned, 
are diverse molecules and can be loosely grouped into three categories: 
glycerolphospholipids (phosphatidylinositol- PI, phosphatidylethanolamine- 
PE, phosphatidylcholine-PC), sphingolipids (ceramide, sphingomyelin), and 
sterols (cholesterol) (Fig 2). Since lipid metabolism pathways involve many 
enzymes and are extensive and interconnected, it would be both laborious and 
inefficient to screen every pathway in a neuronal culture system. It is thus 
Lynette Lim Lanosterol is a survival factor for dopaminergic neurons 
Page 18 
crucial to focus on certain regions of particular pathways. Our first aim was to 
find the lipid metabolic pathway important and specific to dopamingeric 
neurons. To begin, I thus devised an in silico screening method building on 
existing informatics data, consisting of two simple levels of criteria.  
Criterion 1: 
Is the expression pattern of this lipid metabolic gene very different 
among all neurons? I define “very different” by a p-value <0.001 by Sugino et 
al. (2006) array data. If so, I would proceed to criterion 2.  
Criterion 2:  
Is the gene from criterion 1 preferentially expressed in the SNpc? For 
that, I checked in situ expression of that particular gene from the adult mouse 
brain section database provided by the Allen Brain Institute (Lein et al., 2007). 
In situ expression of tyrosine hydroxylase (TH) was used as a reference for 
dopaminergic neurons. As expected, TH is selectively expressed in the SNpc 
and VTA of the midbrain (Fig 3, left panel).  
Using this as a reference for dopaminergic neurons in the brain, I look 
at the lipid metabolic enzymes that have fulfilled our first criterion. For 
example, Hmgcr, an enzyme involved in the biosynthesis of cholesterol (Fig 
4) is expressed at high level in the hippocampus as well as in the SNpc and 
VTA as compared to the other regions of the brain (Fig 3, top right panel). On 
the other hand, phosphatidylinositol-4-phosphate 5-kinase type II alpha 
(pip5k2a) is concentrated in the hippocampus but displays diffuse expression 
in other parts of the brain (Fig 3, bottom right panel). 
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Figure 2: Structures of lipids found in the brain. (A) The headgroup of phosphatidylinositol-
4,5-bisphoshate [PI(4,5)P2] binds to various neuronal protein including adaptor and accessory 
factors of the clathrin coat. Metabolites from PI(4,5)P2 (e.g. Ins(1,4,5)P3 and DAG) function 
in neuronal signaling. (B, C) Glycerophosphatidylethanolamine - PE (B) with ester linked 
fatty acyls (B) and plasmalogens (C) are found in high levels in the brain. Ethanolamine 
plasmalogen has an ether linkage. A major fatty acyl brain PE is arachidonic acid (AA, 20:4), 
with double bond starting at the omega-6 position.  AA is the precursor to signal molecules 
such as prostaglandins. (D) Phosphatidylserine –PS -  is an abundant phospholipid in neuronal 
and synaptic vesicle membranes. Its headgroup binds to C2 domains of many proteins (e.g. 
synaptotagmin). The major fatty acyl chain in PS is docohexeanoic acid (DHA) (22:6), with 
double bonds starting at the omega-3 position (shown here). (E) Phosphatidylcholine – PC - is 
a very abundant lipids in many cells including neurons. Metabolism of PC at the headgroup 
via phospholipase D (PLD) leads to phosphatidic acid, a potent signaling phospholipid, which 
activates lipid kinases. (F, G) Cholesterol (F) and an oxidized derivative (oxysterol, G) can 
influence membrane structure and fluidity. The oxysterol shown has an additional hydroxyl 
group at the C7 ring position. (H, I, J) Ceramide (H) forms the backbone for a large class of 
chemically diverse sphingolipids. Sphingomyelin (I), a ceramide which carries a choline 
headgroup. More complex glycosphingolipids are extremely abundant in brain and myelin. 
Sulfatide (J) is a complex glycosphingolipid that has a sulfate group on the 3-OH position of 
the galactose. 
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Figure 3: In situ expression of Hmgcr and Pip5K2a in ventral midbrain 
 
 
Figure 3: Images from Allen Brain Atlas (www.brain-maps.org) Lein et al., (2007). Green and 
red arrows indicate the VTA and SNpc respectively.  
 
PD animal model: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridines (MPTP) 
injections  
All procedures performed in rodents were in accordance with IACUC 
guidelines. MPTP injections were performed according to previously 
published methods, following the acute schedule (Jackson-Lewis et al., 1995). 
Briefly, C57B6 mice were given four i.p. doses of either 18 mg/kg of MPTP 
(Sigma-Aldrich) or saline (control) every 2 h. Mice were decapitated 48 hours 
after the last dose, and the ventral midbrain and striatum were dissected and 
snap-frozen for subsequent lipid extraction and GC-MS analysis. Previously 
published data using the same protocol showed that at this timepoint about 
35% of dopaminergic neurons have degenerated (Jackson-Lewis et al., 1995). 
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Lipid standards  
Lanosterol, cholesterol, 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC or PC), and desmosterol-d6 (all of highest purity, >99%) were 
purchased from Avanti Polar Lipids. Oxysterol standards α-cholestane, 7α-
hydroxycholesterol, 7β-hydroxycholesterol, 7-dehydrocholesterol, 25-
hydroxycholesterol, and 7-ketocholesterol were obtained from Sigma (St. 
Louis, MO, USA). 7α-Hydroxycholesterol-d7, 7β-hydroxycholesterol-d7, β-
sitosterol-d7, campesterol-d3, lathosterol-d4, and 7-ketocholesterol-d7 were 
purchased from CDN Isotopes (Quebec, Canada). 27-hydoxycholesterol-d5, 
24-hydroxycholesterol, and 24-hydroxycholesterol-d7 were purchased from 
Medical Isotopes (Pelham, AL, USA). Deuterated standards obtained were of 
>95% purity. 
Sample preparation for Gas Chromatography-Mass Spectrometry (GC-MS) 
Sample preparation and GC-MS analyses were performed as 
previously published (Chia et al., 2008; He et al., 2006). Extraction of lipids 
from tissues was carried out using a modified version of the Bligh and Dyer 
method (Bligh and Dyer, 1959). Ventral midbrain (~20-25 mg) or striatum 
tissues (~15-20 mg) were homogenized directly in 600 µl of ice-cold 
chloroform: methanol (1:2). Another 300 µl of chloroform were added to the 
homogenate followed by 450 µl of 1 M KCl. The homogenates were 
centrifuged at 14,000 rpm for 5 minutes at 4°C, and the lower organic phase 
was carefully transferred to a new eppendof tube. All organic phases were 
pooled and dried under vacuum using a speedvac. Samples were stored in -
80°C until derivatization and subsequent GC-MS analysis.  
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Dried lipid extracts were resuspended in chloroform:methanol (1:1) to 
a concentration of 0.1 mg tissue/µl solvent. A 20-µl sample of lipid extract 
was removed and completely dried in a glass vial. For each sample, we added 
a mixture of heavy isotopes: 40 ng of 7α-hydroxycholesterol-d7, 40 ng of 7β-
hydroxycholesterol-d7, 40 ng of 26(27)-hydroxycholesterol-d5, 80 ng of 7-
ketocholesterol-d7, 0.2 µg of 5α-cholestane, 0.2 µg of desmosterol-d6, 0.2 µg 
of lathosterol-d4, 0.2 µg of campesterol-d7, and 0.2 µg of β-sitosterol-d7 in 25 
µl of ethanol. Standards and sample mixtures were dried under a stream of N2 
before adding the derivatizing agent (15 µl acetonitrile and 15 µl BSTFA + 
TMCS; Pierce Thermoscientific). The derivatized samples were analyzed with 
an Agilent 5975 inert XL mass selective detector. Selective ion monitoring 
was performed using the electron ionization mode at 70 eV (with the ion 
source maintained at 230°C and the quadrupole at 150°C) to monitor one 
target ion. Two qualifier ions were selected for the mass spectrum of each 
compound to optimize for sensitivity and specificity. 
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Results: Identification of sterol biosynthetic pathway and lanosterol as 
potential metabolite of importance to dopaminergic neuronal survival. 
In silico pathway analyses identify sterol biosynthetic pathway 
Out of the 3 major lipid pathways, which lead to the generation of 
membrane lipids, we found that the greatest number and percentage of genes 
that fulfill both criteria are from the sterol biosynthetic pathway (Fig 4A). In 
this pathway, 52% (10/19) were positive for both criteria. By contrast, the 
sphingolipid and glycerophospholipid pathways had approximately 10% 
(3/29) and 17% (6/35) representation, respectively. Most interestingly, seven 
consecutive enzymes involved in the metabolic chain from squalene to 
zymosterol fulfill both criteria (Table 3, Fig 4B). Such consistent 
representation string of metabolic pathways was not observed for 
glycerophospholipids (data not shown) and sphingolipids  (Fig 5).  
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Table 3: Genes in cholesterol biosynthesis (see pathway in Fig 4) 
Gene symbol Name *p-value 
** Expression 
in SNpc 
Fdft1 farnesyl diphosphate farnesyl transferase 1 1.89E-11 ++ 
Tm7sf2 transmembrane 7 superfamily member 2 2.44E-10 ++ 
Sqle squalene epoxidase 6.24E-08 ++ 
Pmvk Phosphomevalonate kinase 1.66E-07 + 
Sc4mol sterol-C4-methyl oxidase-like 2.26E-06 ++ 
Idi1 isopentenyl-diphosphate delta isomerase 5.86E-06 - 
Lss lanosterol synthase 1.08E-05 + 
Fdps farnesyl diphosphate synthetase 2.44E-05 +++ 
Ebp 
phenylalkylamine Ca2+ antagonist 
(emopamil) binding protein 8.27E-05 - 
Nsdhl 
NAD(P) dependent steroid dehydrogenase-
like 1.99E-04 ++ 
Hmgcr 
3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase 2.66E-04 +++ 
Cyp51 
lanosterol demethylase/ cytochrome P450, 
family 51 3.33E-04 ++ 
Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 3.75E-04 + 
Mvk mevalonate kinase 1.03E-03 n/a 
Dhcr24 24-dehydrocholesterol reductase 3.27E-03 n/a 
Ggps1 geranylgeranyl diphosphate synthase 1 1.06E-02 n/a 
Sc5d 
sterol-C5-desaturase (fungal ERG3, delta-5-
desaturase) homolog (S. cerevisae) 1.56E-02 n/a 
Cyp27b1 
cytochrome P450, family 27, subfamily b, 
polypeptide 1 1.80E-02 n/a 
Dhcr7 7-dehydrocholesterol reductase 4.52E-02 n/a 
 
*p-value from supplementary data of Sugino et al. (2006).  We consider p<0.001 as 
differentially expressed. 
**Gene expression in SNpc scoring by in situ data from Lein et al., (2007) 
(Scoring key “N/a” = Not analyzed, “-” not expressed or ubiquitously expressed, “+” 
moderately and preferentially expressed in SNpc, “++” expressed preferentially in SNpc; 
“+++” highly preferentially expressed in SNpc) 
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Figure 4: A two-
criteria system was 
used to assess genes 
involved in 
biosynthesis and 
metabolism of the 
main classes of 




Criterion 1 assesses if 
a particular gene is 
differentially 
expressed among 
neurons (by p-value 
of <0.001) in the data 
set from Sugino et al. 
(2006). Criterion 2 
assesses if a 
particular gene is 
preferentially 
expressed (in situ 
hybridization, Lein et 
al. (2007) 
(www.brain-
maps.org) in the 
substantia nigra (SN). 
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genes from each lipid 
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Figure 5: Genes involved in sphingolipid biosynthesis were not differentially 
expressed among neurons or preferentially expressed in SNpc.  
 
 
Figure 5: Graphical representation of the sphingolipid metabolic pathway (modified from 
KEGG). Genes shown in red letters scored positive for criterion 1 (see Fig 3). Genes shown 
with green background scored positive for criterion 2. Genes in yellow letters are genes not 
assessed because they were not included in Sugino et al. (2006).  Only 3 out of 29 genes are 
positive for both criterion 1 and 2 (see also Fig 4A).  
 
Lanosterol level is significantly reduced in affected regions of PD animal 
models.  
If one were to assume that sterol biosynthesis is important for 
dopaminergic neurons as the in silico analysis suggested, then brain sterol 
metabolites might also be altered upon pathogenesis of PD. To address this, 
we compared the levels of sterol metabolites in the two affected regions, 
striatum and ventral midbrain, of control versus a PD model. The PD model of 
choice is pharmacological treatment of animals with MPTP as it is the most 
widely used PD rodent model with a well-established and well-documented 
time course of pathogenesis (Jackson-Lewis et al., 1995; Jackson-Lewis and 
Przedborski, 2007).  Using GC-MS, 9 sterol metabolites were measured. Out 
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of these, only lanosterol, the first cyclic sterol, was reduced by ~50% in the 
two affected brain areas (Fig 6), whereas, no other sterol metabolites differed 
significantly in levels.  
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Figure 6: Lanosterol is specifically depleted in affected brain areas of mice treated with MPTP 
 
 
Figure 6: C576B6 mice were treated with either MPTP or saline. Ventral midbrain and striatum were dissected and lipids extracted for analysis of sterol 
intermediates by GC/MS. Average levels of sterol intermediates from MPTP treated animals (n=4) normalized by the average levels of saline treated 
(control) animals (n=6). Error bars represent standard error of mean (SEM). In both ventral midbrain and striatum, levels of lanosterol are reduced 
significantly in the MPTP treated animals. **p-value <0.01 (Mann Whitney U test). 
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While some previous studies compared levels of brain lipids in PD or 
MPTP animal models to controls, these were limited to the analysis of 
phospholipids and cortices were used rather than the affected areas (ventral 
midbrain and striatum), For example, Julien et al., (2006), measured fatty 
acids (docohexanoic acid, DHA and arachidonic acid, AA, see Fig 2 for 
structure) reasoning that nutritional intake could be easily modified to correct 
for changes in either DHA or AA. However, it is not clear if such lipid profiles 
are representative of the affected region as post-mortem cortices were used 
rather than ventral midbrain and striatum (Julien et al., 2006).  
There are some reports linking sterol lipid metabolism to PD. An 
association study showed that serum cholesterol correlates with PD (Hu et al., 
2008) and low levels of LDL-C may be associated with higher occurrence of 
PD (Huang et al., 2007). However, these remain surrogate observations as 
brain cholesterol is synthesized independently of the rest of the body 
(Dietschy, 2009; Han, 2004; Pfrieger, 2003). 
In rats treated with 3-nitropropionic acid, lathosterol levels were 
lowered in the striatum but higher in serum (Teunissen et al., 2001). Recently, 
Nieweg et al. (2009) published data showing that lanosterol levels are much 
higher in neurons than in astrocytes or oligodendrocytes (Nieweg et al., 2009), 
suggesting that lanosterol could be an essential metabolite for neurons. To 
determine if lanosterol is a survival factor for dopaminergic neurons, we made 
use of primary postnatal ventral midbrain cultures treated with MPP+ or co-
treated with various sterols (chapter 2). 
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Chapter 2: Lanosterol rescues dopaminergic neurons from MPP+  
toxicity in cultures 
Introduction: Primary cultures of ventral midbrain neurons. 
Primary dopaminergic neuronal culture is a technique commonly 
employed to study mechanism of cell death and/or to assess if certain 
compounds could act as survival factors.  While there are many protocols, one 
of the most widely used in the field is the “Sulzer” protocol. Technically, 
dopaminergic neurons are more challenging to culture using postnatal animals 
but they give higher percentage of dopaminergic neurons (30-60% depending 
on area dissected) in contrast to the embryonic cultures (less than 0.5%). More 
importantly, by this stage, dopaminergic neurons in the midbrain have fully 
differentiated, which means that  the observed improved survival is not due to 
induction of differentiation.  
There are a number of technical drawbacks to this system.  Firstly, 
neurons are plated on an astrocytes feeder layer, a requirement for the survival 
of these neurons. Secondly, the number of neurons yield per neonatal animal 
is low, about 20,000 to 25,000 for rats and 10,000-12,000 for mice. Both of 
these drawbacks make it difficult to detect subtly biochemical changes. 
Furthermore, in this culture systems, dopaminergic neurons exposed to toxin 
such as MPP+, the active metabolite of MPTP, could die by many ways such 
as apoptosis, necrosis, or autophagy. Thus, to measure survival, it is laborious 
as one would need to count the total number of individual dopaminergic 
neurons instead of measuring apoptosis by commercial available kits. Finally, 
the postnatal cultures according to the Sulzer’s lab protocol use a growth 
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medium that contains serum. Since we are adding lipids into the cultures, even 
small amounts of serum could mask the effects.  
In this chapter, I modified the published and widely used Sulzer 
protocol for culturing postnatal ventral midbrain. Upon establishing a ventral 
midbrain cultures system that is viable and sensitive to MPP+, I demonstrated 
that exogenous addition of lanosterol rescues dopaminergic neurons from 
MPP+ toxicity. Furthermore, lanosterol, along with cholesterol can induce 
neurite outgrowth. Immunoblot analyses showed an increase expression of 
p35 in neurons treated with cholesterol and lanosterol. The mechanism of 
neurite outgrowth is thus likely via the p35 and subsequent activation of cdk5 
as documented in other studies. Collectively, these results identify lanosterol 
as both a survival factor and inducer of neurite outgrowth. 
 
Material and Methods 
Culturing of postnatal ventral midbrain neurons 
Ventral midbrain cultures were prepared according to previous 
published methods (Rayport et al., 1992) with slight modifications since the 
original method used serum in the medium, which is not suitable for lipid 
addition. In brief, ventral midbrains from postnatal day 0 to day 2 (P0-P2) 
rodents were dissected and digested in papain solution and plated on a glia 
feeder layer. Cells were cultured in serum-free media, neurobasal/B27 
(Invitrogen), with additional supplementation of Superoxide Dismutase-1 
(SOD1), apo-transferrin, and insulin (all from Sigma) to a final concentration 
of 5 µg/ml, 95 µg/ml, and 21 µg/ml respectively. After 1 hour, when cells are 
fully attached, 10 ng/ml of glial derived neurotrophic factor (GDNF, from 
Millipore) was added. To inhibit glial growth, a solution of FDU consisting of 
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16.5 µg/ml of Uridine and 6.7 µg/ml of 5-Fluorodeoxyuridine was added after 
1 day of plating. Cells were cultured for 7 days (DIV7) before treatment with 
MPP+ or co-treatment with sterols/ lipids. 
Lipid and liposomes for cell cultures 
Lanosterol, cholesterol, 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC or PC), and desmosterol-d6 (all of highest purity, >99%) were 
purchased from Avanti Polar Lipids. Lanosterol, cholesterol, and PC were 
dissolved in chloroform:methanol (1:1). Cholesterol or lanosterol was mixed 
in equimolar proportion with PC and dried by vacuum in a Speedvac 
(Thermosavant). The lanosterol/PC or cholesterol/PC mixture was 
resuspended and sonicated in culture medium on the day of treatment to make 
a 0.5 mM stock liposome. Each type of stock liposome was used in the 
neuronal cultures within a day of preparation.  
Fluorescence microscopy and quantification of dopaminergic neuronal 
survival  
Ventral midbrain cultures plated on 12 mm coverslips were treated for 
24 hours with 10 µM of MPP+ and or co-treatment with 5 µM PC, 5 µM 
cholesterol, or 5 µM lanosterol. After aspirating the medium, cells were 
washed 3 times with 1 X PBS to remove all dead cells. Cells were then fixed 
with 4% paraformaldehyde for 20 minutes, followed by permeabilization and 
blocking using 5% FBS in 0.1% TritonX-100 for 30 minutes. Coverslips were 
then stained with anti-TH (secondary alex-fluor488 – green) and TUJ1 
(secondary alexfluor555- red). Anti-mouse or rabbit alex-fluor488 or 555 dyes 
(1:1000) were purchased from Molecular Probes/ Invitrogen. Two types of 
cells were counted: TUJ1 positive and TH positive cells by using an Olympus 
fluorescence scope with Fluorescein and Rhodamine filter sets. Every neuron 
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on the entire 12 mm coverslip was assessed. Percentage of dopaminergic 
neurons for each condition was determined by number of TH+/TUJ1+. 
Typically, for control conditions, each coverslip consists of 2000-3000 TUJ1 
positive and about 400-1200 are TH+. For each treatment, we assessed 4-6 
coverslips in each independent experiment. The averages of 4-5 independent 
experiments were reported in the figures.  
Culturing hippocampal neurons 
 
E18.5 hippocampal neurons were cultured according to previously 
described method in neurobasal/B27 (Kaech and Banker, 2006). Briefly, 
neurons were plated on a wax-dotted 15 mm coverslips coated with 1 mg/ml 
of poly-D-lysine (Sigma). Two hours after plating, when neurons have 
attached, the coverslips were flipped into a 12-well plate containing a glial 
feeder layer. For neurite outgrowth experiments, neurons were plated at 
extremely low density of 150 cells/mm2. Various concentrations of cholesterol 
and lanosterol were added at this time of coverslip flipping. After 48 hours, 
neurons were either fixed for immunocytochemistry or both neurons and glia 
feeder lysed for protein extraction.  
Neurite outgrowth measurements 
Hippocampal neurons were stained with an anti-Tau1 Ab (Chemicon) 
and imaged using a spinning disc confocal miscroscope. Total neurite (axon) 
length per cell was quantified for each condition using the neurite outgrowth 
segmentation algorithm (Metamorph v7.1).  
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Western blot 
For western blot, cells in cultures were washed 3 times with 1X PBS 
after media was aspirated. Cells were then lysed in 100 µL of RIPA buffer (50 
mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 
mM EDTA) supplemented with a cocktail of protease inhibitors (Complete 
Mini-EDTA inhibitors, Roche Diagnostics). Approximately 20 µg of cell 
protein lysate were loaded in each well of a 10% polyacrylamide gel 
containing 0.1% SDS. Proteins were then transferred to nitrocellulose 
membrane. Membrane was immunoblotted with polycolonal antibodies rabbit-
anti-cdk5 (C8) 1:500, and rabbit anti-p35 (C19) 1:1000, from Santa Cruz. 
Monoclonal mouse-anti-actin (1:10,000) was purchased from Sigma. 
Monoclonal mouse-anti-neuronal tubulin (TUJ1) (1:10,000) was purchased 
from Convance. Secondary antibodies anti-rabbit or mouse peroxidase 
conjugated (1:10,000) for western blots were purchased from Biorad. 
Immunoblot was visualized with ECL reagent from Pierce Thermoscientific.  
Statistical analyses 
Error bars represent standard errors of measurements (SEM) and p-
values were calculated by Student’s t-test. 
 
Results: Effects of sterol treatments of primary neurons.  
Primary ventral midbrains cultured in the modified medium survived 
well. Typically, there are about 25-30% of dopaminergic neurons as judged by 
TH+ staining (Fig 7). It is also important to note that the TH+ neurons are also 
selectively sensitive to MPP+ toxicity at the concentration of 10 µM (Fig 7A 
versus 7B), resulting in about 50% decrease of TH+ neurons (p<0.001). 
However, the number of dopaminergic neuronal death did not increase 
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drastically with increasing dose of MPP+. At high MPP+ concentrations, there 
were also more “unselective” cell death (data not shown, personal 
observation). Therefore, I decided to use the lowest MPP+ concentration (10 
µM) to test the survival effects of lanosterol.   
After establishing the ventral midbrain cultures, we asked whether 
exogenous addition of lanosterol protects dopaminergic neurons against 
MPP+-induced cell death. Primary postnatal neuron cultures from ventral 
midbrain were treated with MPP+, and the survival of dopaminergic neurons 
was determined in the absence or presence of exogenously-added lanosterol. 
48% of dopaminergic neurons survived upon treatment with MPP+ under 
these culture conditions (Fig 8A, 8C). Co-incubation of MPP+ with 
phosphatidylcholine (PC, vehicle control) or cholesterol did not improve 
survival of dopaminergic neurons (Fig 8B, 8C). In contrast, co-treatment of 
the cultures with MPP+ and lanosterol increased survival of dopaminergic 
neurons to 76% (Fig 8B, 8C). Thus, lanosterol rescues dopaminergic neurons 
from MPP+-induced cell death. 








Figure 7: Ventral midbrain cultures (A) control (B) with 10µM of MPP+, stained with 
dopaminergic neuron marker – TH (green), neuronal marker TUJ1 (red) and nucleus dye 
DAPI (blue). White arrowheads show nucleus of astrocytes (feeder layer), which have bigger 
nucleus than neurons. Scale bar is 100µm. (C) Graphical representation of percentage of 
dopaminergic neurons (n = 3). Error bars represent +/- SEM.  
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Figure 8: Lanosterol rescues dopaminergic neurons in MPP+-treated postnatal ventral midbrain cultures 
 
 
Figure 8: Fluorescence images of 
primary ventral midbrain cultures 
(DIV7) stained with anti–tyrosine 
hydroxylase (TH), a marker for 
dopaminergic neurons. (A) Control 
cells (no treatment) and cells treated 
with 10 µM MPP+; (B) co-treated 
cells for 24 h with 10 µM MPP+ and 
5 µM of phosphatidylcholine (PC, 
left panel), lanosterol (middle panel), 
or cholesterol (right panel). Scale 
bars in A and B represent 200 µm. 
(C) Plot of fold changes of each 
treatment relative to control. Y-axis 
shows the average percentage of 
TH+ neurons from each treatment 
condition divided by the average 
percentage of TH+ neurons in 
control. Error bars represent SEM 
from four to five independent 
experiments. ***p < 0.001 between 
lanosterol/MPP+ and MPP+. 
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In addition to survival, dopaminergic neurons treated with lanosterol 
appear to have longer neurites. Since survival factors cause proliferation in 
dividing cells (Chaudhary and Hruska, 2001; Holmstrom et al., 2008) and may 
increase neurite length in neurons (Bonnet et al., 2004; Ma et al., 2009), it was 
thus important to establish if lanosterol increased neurite length.  From a 
technical perspective, it was difficult to measure neurites length of 
dopaminergic neurons accurately. This is because these neurons in cultures do 
not express their marker, TH, till after days in vitro 5 (DIV 5) (data not 
shown). By this stage, most neurites are far too long to trace accurately in a 
single field of view. Furthermore, postnatal dopaminergic neurons could only 
be grown in culture with direct contact with an astrocyte feeder. Thus, in order 
to investigate, biochemically, the effects in various cell types, I chose to use 
hippocamal neurons in co-culture “Banker style” cultures to assess neurite 
outgrowth, since their developmental stages are well documented (Kaech and 
Banker, 2006). In this hippocampal neuron-astrocytes co-cultures, neurons are 
plated on glass coverslips while astrocytes are grown on the culture dish. 
Coverslips with paraffin dots are inverted to face the monolayer glial cells 
allowing for free exchange of media and biochemical isolation of individual 
cell types. 
Using an unbiased software-based quantification, I measured the 
neurite length two days after plating and showed that lanosterol significantly 
increased neurite length from an average length of 59 µm in the non-treated 
condition to 132 µm  (Fig 9A, 9B). This effect was also observed with 
cholesterol, demonstrating that both sterols have growth promoting properties. 
To determine if these two sterols activate known growth-promoting signaling 
Lynette Lim Lanosterol is a survival factor for dopaminergic neruons 
Page 40 
pathways, we biochemically assayed the expression level and activation state 
of Erk, Akt, Gsk-3β, and p35/cdk5. There were no dramatic differences in 
phospho-Akt or phospho-Gsk-3β(Ser9) levels (data not shown). Interestingly 
however, the addition of sterols induced an increase of p35 expression, the 
activator of cdk5, while expression levels of cdk5 itself remained unchanged 
(Fig 9C). This effect is neuron-specific as it was not observed in astrocytes. 
The expression of the neuron-specific microtubule-associated protein, TUJ1, 
is increased in sterol treated neurons. This is consistent with the neurite 
outgrowth assays (Fig 9), whereby longer neurites should have more 
microtubles. Therefore, lanosterol as well as cholesterol promote neurite 
outgrowth and induce increased expression of the activator of cdk5, p35.  
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Figure 9: Tau1 staining and segmentation analysis of hippocampal neurons cultures. Scale bar 
represents 20µm. Lanosterol and cholesterol lead to extended neurites. (B) Total neurite 
length was assessed by segmentation software using Metamorph. 200-400 neurons were 
assessed per experiment. Error bars represent SEM of 3 independent experiments. **p<0.01 
and ***p<0.001 between treatment conditions and control conditions were assessed by two 
tailed Student t-test. (C) Immunoblots of neurons and astrocytes (DIV 3) grown in “Banker 
style” co-cultures (see methods) and treated with various lipids for 48 hours. Antibodies used 
are anti-p35 (an activator of cyclin dependent kinase 5, cdk5), cdk5 (cyclin dependent kinase 
5), TUJ1 (neuronal class III tublin). Lanosterol and cholesterol induce expression of p35 in 
neurons but not in astrocytes. Results shown are representative of 3 independent experiments. 
 
 
Cholesterol biosynthesis has been previously shown to be essential to 
nerve regeneration in various models ranging from in vivo optic nerve crush 
(Heacock et al., 1984), to in vitro cultured rat sympathetic neurons (de Chaves 
et al., 1997). I demonstrate here that lanosterol and cholesterol enhance neurite 
outgrowth. Furthermore, I find that these sterols could also elevate the activity 
of intracellular kinases such as cdk5 via increased expression of p35. It has 
been reported and well-established that cdk5 is regulated by its activator p35 
and could together induce neurite outgrowth in various models (Hahn et al., 
2005; Namgung et al., 2004). In addition, a number of factors, such as 
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interferon gamma (Song et al., 2005), and Fas (Desbarats et al., 2003) could 
induce the increase in levels of p35. However, no lipid or sterol metabolite had 
been shown to increase p35 expression level. These results thus suggest a 
novel, sterol-dependent activation mechanism for p35/cdk5, which may 
promote neurite outgrowth.  
Yet, this outgrowth mechanism via increase expression of p35 in 
neurons is unlikely to be the same to elicit the rescue effects seen in 
dopaminergic neurons. Firstly cholesterol, which also increases neurite 
outgrowth and expression of p35, fails to rescue dopaminergic neurons. 
Furthermore, in ventral midbrain cultures treated with lipids and MPP+, there 
were no significant changes in p35 levels (see chapter 4). To determine 
lanosterol’s mechanism of rescue, I started to biochemically screen a number 
of pathways (chapter 3).  
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Chapter 3: Biochemical analyses of metabolic pathways. 
Introduction: Cross-talk of metabolic pathways  
Since sterol metabolites can be converted to other precursors by 
endogenous enzymes, it is important to determine if the addition of lanosterol 
would change other metabolites. Firstly, does addition of lanosterol change 
other sterols in the cholesterol biosynthetic pathway? Secondly, does 
lanosterol affect levels of other metabolites, which are reported as survival 
factors?  
To answer the first question, I measured a number of metabolites in the 
sterol biosynthetic pathway. This would in part answer if addition of 
lanosterol alters other metabolites. In addition, another important metabolite to 
measure is ubiquinone or Coenzyme Q (CoQ), the lipid electron carrier that 
localizes mainly in the mitochondria. CoQ has a quinone chemical group and 
varying length of isoprenyl subunits. Thus, in the cell, there are cross talks 
between biosynthesis of sterols and CoQ since they both share isoprenyl as 
precursors (Fig 10). In the context of PD, CoQ has been shown to be 
beneficial to a subset of PD patients and is neuroprotectinve in the MPTP 
animal models (Beal et al., 1998; Cleren et al., 2008; Galpern and Cudkowicz, 
2007; Muller et al., 2003; Yang et al., 2009).  
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Figure 10: Cross-talk of sterol and  ubiquinone biosynthesis 
 
 
Figure 10: Simplified pathway of cross-talk between sterol and ubiquinone biosynthesis in 
mammalian cells. Both pathways use isoprenyl units as precursors 
 
Materials and Methods: Lipid extraction and measurements 
Sample preparation for Gas Chromatography-Mass Spectrometry (GC-MS) 
Approximately 400,000 cells were used for each condition. After 
treatment, cells were washed 3 times with cold PBS and scraped with 400 µl 
ice-cold methanol and transferred to a 1.5-ml Eppendoff tube. Then, 200 µl of 
chloroform was added, followed by 1 minute of vortexing.  300 µl of 1 M KCl 
was added. The homogenates were centrifuged at 14,000rpm for 5 minutes at 
4°C to separate the phases and the lower organic phase was carefully 
transferred to a new Eppendof tube. Aqueous phases were re-extracted twice 
with 300 µl of chloroform. All organic phases were pooled and dried under 
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vacuum using a Speedvac (Thermosavant) and stored in -80°C until 
derivatization and subsequent GC-MS analyses.  
For each sample, I added a mixture of heavy isotopes, 20 ng of 7 
alphahydroxycholesterol-d7, 20 ng of 7 beta-hydroxycholesterol-d7, 20 ng of 
26 (27)-hydroxycholesterol-d5, 40 ng of 7-ketocholesterol-d7, 0.1 µg 5-alpha 
cholestane, 0.1 µg of desmosterol-d6, 0.1 µg of lathosterol-d4, 0.1 µg of 
campesterol-d7, and 0.1 µg of beta-sitosterol-d7 in 25 µl of ethanol. Standards 
and sample mixture were dried under a stream of N2 before the addition of a 
derivatizing agent, 15 µl acetonitrile and 15 µl BSTFA + TMCS (Pierce 
Thermoscientific). The derivatized samples were analyzed using Agilent 5975 
inert XL mass selective detector. Selective ion monitoring was performed 
using electron ionization mode at 70 eV (with ion source maintained at 230°C 
and the quadrupole at 150°C) to monitor one target ion. Two qualifier ions 
were selected for each compound’s mass spectrum to optimize sensitivity and 
specificity. 
 
Measurement of Coenzyme Q 
 For each condition, 3 to 4 million neurons (DIV 7) were treated with 
various lipids and incubated for 24 hours. Cells were washed twice with cold 
PBS and were scraped in 0.5 ml of cold PBS. Cells were centrifuge at 1000g 
to pellet and PBS was removed. To re-suspend the cell pellet, 100 µl of fresh 
PBS was added. 750 µl of hexane:ethanol (5:2 v/v)  was added and vigorously 
vortexed for 1 minute.  To extract coenzyme Q, 400 µl of the organic phase 
were collected and dried completely with N2.  
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Agilent HPLC 1200 system (Agilent) coupled with an Applied 
Biosystems 3200 QTrap mass spectrometer (Applied Biosystems, Foster City, 
CA) was used for measurement of coenzyme Q8, Q9, Q10 and free 
cholesterol. Chromatographic separation was carried out using an Agilent 
Zorbax Eclipse XDB-C18 column (i.d. 4.6 × 150 mm). HPLC conditions were 
as follows: (1) chloroform:methanol 1:1 (v/v) as the mobile phase at a flow 
rate of 0.5 ml/min; (2) column temperature: 30°C; (3) injection volume: 10 µl.  
The LC-MS instrument was operated in the positive atmospheric pressure 
chemical ionization (APCI) mode with a vaporizer temperature of 500ºC, and 
corona current of 3 µA. Coenzyme Q6 was used as an internal standard and 
monitored using MRM transition of 591.4197.0. MRM transitions of 
727.5197.0, 795.5197.0 and 863.6197.0 were set up for analysis of 
coenzyme Q8, Q9 and Q10, respectively.  
 
Results: Metabolic changes upon sterol additions 
 
To determine if addition of lanosterol affects other sterol metabolites, I 
analyzed squalene, lanosterol, lathosterol, 7-dehydrocholesterol, desmosterol, 
cholesterol, 7-beta-hydroxylcholesterol, 7-keto-cholesterol, 24-
hydroxylcholesterol in cell extracts by GC-MS. Cultures were treated with 
formulations of lanosterol or control lipids (cholesterol or PC). Cells were 
then washed and extracted for lipid analysis, which revealed two key findings: 
(1) a surprising capacity of the cells to accumulate lanosterol (Fig 11A, 11B); 
(2) among the precursors measured, lanosterol was the only metabolite that 
was significantly increased under any of the three treatment regimes.  
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It should be noted that in these experiments the postnatal dopaminergic 
neurons were grown in direct contact with glia cells. Thus, we cannot rule out 
the possibility that astrocytes rather than neurons took up lanosterol and 
mediate neuroprotection. To address this, we repeated the experiment with 
hippocampal neurons (rather than mid-brain derived neurons which are mixed 
cultures with approximately 30% dopaminergic neurons) cultured according to 
Banker’s method (Kaech and Banker, 2006), which allows physical separation 
and extraction of individual cell types. We found that lanosterol levels 
increased in both neurons and astrocytes to a similar extent upon treatment 
with exogenous lanosterol (Fig 11C, 11D). While we cannot rule out a 
contribution of astrocytes in lanosterol-mediated neuroprotection, our result 
indicate that lanosterol levels are significantly elevated in neurons upon 
treatment, consistent with a direct role of lanosterol in promoting survival of 
dopaminergic neurons.   
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Figure 11: (A) GC-MS profiles of lanosterol ( m/z 393, red) and internal standard, deuterated ß-sitosterol, 
(m/z 493, black) of ventral midbrain cultures incubated (24h) with various lipid treatments. (B) Graphical 
representation of cellular levels of sterol intermediates with various treatments normalized to control (no 
treatment conditions) in ventral midbrain mixed cultures, (C) neurons only (right)  and astrocytes only (left) 
in “Banker” style hippocampal cultures. Error bars represent SEM from 3 independent experiments. ***p-
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Since the addition of lanosterol causes an increase in lanosterol (Fig 
10), this could in turn result in the increase of CoQ as the endogenous isoprene 
could be converted to ubiquinone instead of sterols. CoQ have been shown to 
improve survival of dopaminergic neurons in MPTP animal model and to 
benefit some PD patients in clinical trials (Beal et al., 1998; Cleren et al., 
2008; Muller et al., 2003; Shults et al., 2002; Spindler et al., 2009). Therefore, 
it is possible that neurons with increased lanosterol could have altered CoQ 
levels. In mammalian cells, Q9 is the most abundant. Using LC/MS, Q9, along 
with two other lower abundant species of CoQ, corresponding to Q8 and Q10, 
were measured in hippocampal neurons treated PC, cholesterol, or lanosterol. 
However, there were no significant changes in all 3 species upon lanosterol 
treatment (Fig 12). It is thus unlikely that the survival effect seen by lanosterol 
addition is due to changes in ubiquinone levels.  
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Figure 12: Coenzyme Q (CoQ) levels in neurons normalized to total cholesterol in cultures in 
various treatment conditions. Error bars represent SEM over 4 independent experiments. 
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Chapter 4: Immunoblot and immunofluoresence analyses of surivival 
pathways   
 
Introduction: Rational for assaying levels of SREBP2, Gsk-3β, p35/cdk5, and 
LSS 
In order to elucidate the mechanisms by which lanosterol may act as a 
survival factor, I probed a few pathways that have been shown in 
neuroprotection based upon the literature by immunoblot. For example, 
previous studies have shown that activation of the Sterol Regulatory Element 
Binding Protein 2 (SREBP2) is involved in exacerbating neuronal 
degeneration (Fernandez et al., 2009) and inhibition of SREBP2 attenuate cell 
death (Luthi-Carter et al., 2010). The GSK-3β pathway has been implicated in 
both Parkinson’s and Alzheimer’s disease, and inhibition of phosphorylation 
of ser9 in Gsk-3β appears to have beneficial effects (see recent review 
(Garcia-Gorostiaga et al., 2009).  Based upon data in this thesis, the addition 
of lanosterol can induce neurite outgrowth and increase expression of p35 
(chapter 2, Fig 9C). Thus, it is possible that p35/cdk5 could be a mechanism of 
neuroprotection. In addition, since I observed a reduction in lanosterol levels 
(chapter 1, Fig 6) in MPTP animal, it is likely that MPP+ results in mis-
regulation of lanosterol synthase (LSS), the rate-limiting enzyme in lanosterol 
synthesis (Mori et al., 2007).  
 
Material and Methods: 
Western blot analyses 
Ventral midbrain cultured cells were washed three times with PBS. 
Cells were lysed in 100 µL of RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-
40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA), supplemented 
with a cocktail of protease inhibitors (Complete Mini-EDTA inhibitors, Roche 
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Diagnostics). 20 µg of cell protein lysate were loaded in each well of a 10% 
polyacrylamide gel containing 0.1% SDS. After electrophoresis, proteins were 
transferred to nitrocellulose membrane and probed with the following 
antibodies: (i) rabbit anti-p35 (C19; 1:1000, Santa Cruz Biotechnology), (ii) 
rabbit anti–lanosterol synthase (1:1000, AVIA), (iii) rabbit anti–tyrosine 
hydroxylase (TH) (1:20,000, Covance), (iv) rabbit anti-SREBP2 (1:1000, 
Abcam), (v) rabbit anti-calnexin (1:2000, Abcam), (vi) rabbit anti-
VDAC/porin (1:2000, Abcam), (vii) rabbit anti-pGSK-3α/β (ser21/9) 1:1000, 
Cell Signaling). Peroxidase-conjugated anti-rabbit or anti-mouse secondary 
antibodies (1:10,000) were purchased from Bio-Rad. Immunoblots were 
visualized with ECL reagent from Pierce Thermoscientific.  
Confocal microscopy and co-localization studies 
Ventral midbrain cultures in control and MPP+ treated cells were 
stained with rabbit anti-LSS (1:100), monoclonal mouse anti-TOMM20 
(1:1000, Abcam) or monoclonal mouse anti-KDEL (1:1500, Abcam), and 
sheep anti-TH (1:500, Abcam). The secondary antibodies, goat anti-mouse 
Alexa-fluor 555, goat anti-rabbit Alexa-fluor 488, and donkey anti-sheep 
Alexa-fluor 633, were obtained from Invitrogen. Cells were imaged with a 
laser-scanning confocal microscope (LSM510, Carl Zeiss) with excitation and 
emission filters meeting the secondary Alexa-fluor antibody dye 
specifications. Images were taken using a 63X objective. To quantify co-
localization, we plotted the pixel intensities of LSS versus (vs) KDEL or 
TOMM20 from regions of interest (ROIs) drawn around single neurons (either 
TH positive or negative), and calculated the linear regression coefficient, R2, 
for 16-22 individual ROI/neuron. 
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Results: Lanosterol effects on various signaling pathways 
To explore the mechanisms underlying lanosterol-mediated 
neuroprotection, we investigated the effects of MPP+ and lanosterol on 
various signaling pathways previously implicated in cellular metabolism and 
neurodegeneration. First, we examined the expression level of sterol response 
element binding protein (SREBP2, Fig 13A), a transcription factor reported to 
exacerbate neuronal degeneration (Fernandez et al., 2009). We found that 
MPP+ induced a modest increase in SREBP2 levels, which was not rescued 
by lanosterol addition (Figure 13A, top panel). We also checked for levels of 
p35, the activator of cdk5, since the genetic ablation of p35/cdk5 confers 
neuroprotection in the MPTP model (Neystat et al., 2001). While we observed 
a decrease in p35 levels in MPP+-treated cells, addition of lanosterol did not 
restore p35 expression to control levels (Figure 13A, 2nd panel from top). 
Consistent with previous findings implicating Gsk-3β Ser9 phosphorylation in 
PD pathogenesis (Garcia-Gorostiaga et al., 2009), we found an increase of 
phospho-Gsk-3β levels in MPP+-treated cells. However, this increase was not 
affected by the addition of lanosterol (Figure 13A, 3rd panel from top). 
Finally, we examined the levels of lanosterol synthase (LSS), the 
enzyme that catalyzes cyclization of oxidosqualene, the rate limiting step in 
lanosterol synthesis (Mori et al., 2007). The levels of LSS did not markedly 
change upon MPP+ addition (Figure 13A, 4th panel from top). Interestingly, 
however, we observed a different localization pattern of LSS in MPP+-treated 
dopaminergic neurons. LSS immunostaining appeared much more punctate 
after MPP+ treatment (Figure 13B), suggesting that drug-induced 
redistribution of LSS and lanosterol to a different intracellular compartment.  
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We thus proceeded to examine the subcellular localization of LSS in control 
and MPP+ treated dopaminergic neurons.   
Lynette Lim Lanosterol is a survival factor for dopaminergic neruons 
Page 56 
 
Figure 13: Analyses of SREBP2, Gsk-3β, p35/cdk5, and LSS in ventral midbrain treated 




Figure 13: (A) Immunoblot analyses of several factors previously linked to neuroprotection in 
Parkinson’s disease and/or MPTP treatment. (B) Immunofluorescence images of ventral midbrain 
neurons stained with LSS and TH, treated with or without MPP+. LSS appears more punctate in TH+ 
neurons upon MPP+ treatment. Scale bar represents 10 µm. (C) Subcellular fractionation of liver tissue. 
Mitochondrial – M, microsome/ER – ER, and cytosolic – C, fractions were purified from whole liver – 
WL. Immunoblot of calnexin (ER maker) and VDAC/porin (mitochondrial marker) were used to assess 
the purity of each fraction. LSS showed a clean single band at the expected weight of 78 kDa and is 
enriched in the ER fraction. A small amount of LSS is also detected in the mitochondrial fraction.  
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As reported by several groups, mammalian LSS is localized to the 
microsomal fraction (Bloch et al., 1957; Tchen and Bloch, 1957; Yamamoto 
and Bloch, 1969; Yamamoto et al., 1969). Rodent LSS has been purified, and 
the detected molecular weight is 78 kDa (Kusano et al., 1991). Crystal 
structure of human LSS reveals a putative membrane insertion domain in the 
ER (Thoma et al., 2004). By subcellular fractionation of whole rat liver 
tissues, we isolated mitochondria, microsomes, and cytosolic protein lysates 
and showed that the endogenous localization of LSS is enriched in the 
microsomal fraction (Fig 13C), consistent with the literature. However, I could 
also detect small amounts of LSS in the mitochondrial fraction (Fig 13C). This 
does not appear to be residual microsomal contamination in the mitochondria 
fraction because in the lanes loaded with 5 and 10 µg of mitochondrial protein, 
I do not detect the ER marker, calnexin (Fig 13C).  
Consistent with our biochemical fractionation data, we found that LSS 
co-localized with an ER marker (KDEL) in both dopaminergic and non-
dopaminergic neurons (Figure 14A). Extensive overlap between LSS and the 
ER marker was observed for both dopaminergic and non-dopaminergic 
neurons (R2 = 0.83 ± 0.01 and 0.84 ± 0.01 respectively). Less overlap was 
found between LSS and TOMM20 (a mitochondrial marker) for both 
dopaminergic and non-dopaminergic neurons (R2 = 0.70 ± 0.02 and 0.69 ± 
0.02 respectively, Fig 14A, 2nd panel from the top). This pattern changed 
noticeably in dopaminergic neurons treated with MPP+. The co-localization of 
LSS with TOMM20 was markedly increased (R2 = 0.856 ± 0.01, Fig 14A, 
bottom last panel), with concomitant reduction in the overlap of LSS with 
KDEL (R2 = 0.69 ± 0.02, Fig 14A, 2nd panel from the bottom). Translocation 
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of LSS from the ER to mitochondria was also observed in dopaminergic 
neurons co-treated with MPP+ and lanosterol (Fig 14B). MPP+ did not, 
however, affect LSS localization in non-dopaminergic neurons (Fig 13B, 
14B), consistent with the inability of these cells to take up MPP+. These data 
indicate that a significant fraction of LSS redistributes from the ER to 
mitochondria in dopaminergic neurons exposed to MPP+, suggesting that LSS 
(and its product lanosterol) may have a role in regulating mitochondrial 
function. 
In addition, the translocation of LSS in dopaminergic neurons under 
toxic insult is also seen in mouse embryonic fibroblast (MEF) under serum 
starvation. As shown (Fig 15), LSS in MEF grown in normal 10% serum 
conditions co-localizes with the ER marker, KDEL (Fig 15A). After serum 
starvation for 12-16 hours, LSS localizes to the mitochondria, recapitulating 
the effects seen in dopaminergic neurons with MPP+ (Fig 14). We thus 
believe that the mitochondrial pools of LSS might have specific functions in 
connecting sterol metabolism to compromise cellular energetic. 
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Figure 14: Lanosterol synthase (LSS) is redistributed from ER to mitochondria in 
dopaminergic neurons upon addition of MPP+. 
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Figure 14: (A) Confocal images of ventral midbrain neurons stained with TH (white), LSS 
(green), either KDEL (red, 1st and 3rd panels from the top) or TOMM20 (red, 2nd and 4th 
panels from the top) in either control or with MPP+. White boxes show dopaminergic neurons 
as determined by TH+ staining. Right panels show pixel intensity correlation plots of LSS 
with either KDEL or TOMM20 in dopaminergic neurons. Scale bar represents 10 µm. (B) 
Average R2 values (a measure of co-localization) of two classes of neurons in control and 
MPP+ treated conditions. In control, R2 values from co-staining of KDEL-LSS, n = 26 and n 
= 27, TOMM20-LSS, n = 20 and n = 21, were assessed for dopaminergic and non-
dopaminergic neurons respectively. In MPP+-treated cells, R2 values from co-staining of 
KDEL-LSS, n = 20 and n = 20, for TOMM20-LSS, n = 18 and n = 17, were assessed for 
dopaminergic and non-dopaminergic neurons respectively. In MPP+/lanosterol co-treated 
cells, R2 values from co-staining of KDEL-LSS, n = 18 and n = 23, for TOMM20-LSS, n = 
19 and n = 18, were assessed for dopaminergic and non-dopaminergic neurons respectively.  
****p < 0.00001 between control and MPP+ were calculated by two-tailed Student’s t-test.  
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Figure 15: MEF grown in (A) Control – 10% serum or (B) serum starved for 12-16 hours were 
stained with LSS and ER-marker, KDEL, or mitochondrial marker, Grp75. Intensity of LSS versus 
KDEL or Grp75 were plotted on cross-correlation plots with linear regression fit (R2 ) values. LSS in 
MEF grown in serum co-localizes with KDEL but upon serum starvation, LSS co-localizes with 
Grp75. Scale bar represent 10 µm. 
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There are a number of interpretations to the striking redistribution of 
LSS from ER to mitochondria in dopaminergic neurons upon MPP+ 
treatment. First, the enzyme is mis-localized and the mitochondrial form of 
LSS is non-functional. However, recently, lipidomic analysis of macrophages 
during stimulation with LipidA (a condition which can be expected to lead to 
oxidative bursts similar to MPP+ induced ROS stress) shows that generation 
of lanosterol is a pronounced response in several cellular compartments 
including mitochondria (Andreyev et al., 2010). Therefore, it is likely that 
mito-LSS is functional.  
 A second explanation is that LSS is re-organized as an immediate 
response to the MPP+ and that mito-LSS and ER-LSS have distinct roles. In 
ER, LSS generates lanosterol which will be further metabolized to cholesterol 
by the cholesterol synthetic machinery resident in that organelle. In 
mitochondria, the lanosterol might serve other purposes, as a mediator for 
mitochondrtial function or precursor of an unknown metabolite/membrane 
structure. Thus, lanosterol might be required in heightened amounts under 
such conditions, which in part could explain its lowered levels in mice after 
prolonged exposure to MPTP (chapter 1, Fig 6). Mitochondria are increasingly 
believed to be involved in autophagic responses to various extents (Hailey et 
al., 2010).  ER-mitochondrial connections could provide lipid for autophagic 
membrane formation (Hailey et al., 2010). This reasoning would argue for a 
more general relevance of our observations. Indeed, re-localization of LSS 
from ER to mitochondria is not limited to MPP+ stressed dopaminergic 
neurons. I observed similar re-localization in serum-starved fibroblast (Fig 
15), again consistent with induction of the autophagic cell response.  
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 Third, re-distribution of enzymes is commonly seen in cells during 
stress. For example, examination of > 800 yeast strains expressing various 
GFP coupled proteins revealed altered locations of certain proteins upon stress 
response (Narayanaswamy et al., 2009). The authors noted that these proteins 
are usually involved in intermediary metabolism. Movement of proteins or 
metabolites from ER to mitochondria is an important stress response, and 
impaired functions have been implicated in some neurodegenerative diseases. 
For example, Mitofusin-2, a protein that mediates ER-Mito trafficking, causes 
the inherited motor neuropathy disorder, Charcot-Marie-Tooth type IIa (de 
Brito and Scorrano, 2008). Disruption of mitofusion-2 dramatically impaired 
starvation-induced autophagy (Hailey et al., 2010). Two genes involved in 
familial PD, PINK1 and Parkin, accumulate and redistribute respectively to 
mitochondria upon mitochondrial uncoupling (Narendra et al., 2008), which is 
important for mitophagy (Geisler et al., 2010a). Importantly, translocation of 
Parkin to mitochondria has etiological significance as a number of 
pathologically associated Parkin mutants fail to translocate (Matsuda et al., 
2010; Okatsu et al., 2010).  
 Taken together, if one were to assume that the translocation of LSS to 
the mitochondria has important function, it is likely that lanosterol has roles in 
regulating mitochondria physiology. To determine the roles of lanosterol in 
mitochondria and how lanosterol could be neuroprotective, we used a live-cell 
imaging approach to assess mitochondria function (Chapter 5).  
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Chapter 5: Elucidating the mechanism of lanosterol’s neuroprotection on 
dopaminergic neurons by imaging techniques.  
Introduction: Mitochondrial membrane potential and JC-1 dye 
One aspect of mitochondrial physiology can be assessed by measuring 
changes in mitochondrial membrane potential, ΔΨ. Mitochondrial membrane 
potential is a measurement of both electrical and chemical gradient which 
drive hydrogen ions across the inner membrane during the process of electron 
transport and oxidative phosphorylation, the mechanism behind ATP 
production. In the cell, this process is never completely coupled, allowing 
electron to be transported without ATP production. If, as we observed, LSS 
localization can be altered from ER to mitochondria upon toxin insult in 
neurons by MPP+, it is reasonable to expect that lanosterol could be of 
importance to mitochondrial function.  
In neurons, induction of such “mild” uncoupling by lipids, such as 
CoQ, or proteins such as uncoupling proteins, UCPs, or brief exposure to 
artificial uncoupler such as FCCP (carbonyl-cyanide-4-(trifluoromethoxy)-
phenylhydrazone) have been shown to be neuroprotective (Andrews et al., 
2005; Conti et al., 2005; Horvath et al., 2003; Mattiasson et al., 2003; Stout et 
al., 1998).  If “mild” uncoupling were to occur upon lanosterol addition, the 
measurement of ΔΨ would decrease and this could be a mechanism of 
neuroprotection. Futhermore, alteration in mitochondrial membrane potential 
in mammalian cells can cause PINK1’s recruitment of Parkin. And since PD-
associated Parkin mutations cause a decrease in mitophagy in (Geisler et al., 
2010b), we thus asked if lanosterol could also mediate autophagosome 
formation in dopaminergic neurons.  
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To investigate whether ΔΨ is altered in neurons upon addition of 
lanosterol, we employed the lipophilic cationic dye, JC-1. The dye can be 
loaded in live cells and selectively enters into mitochondria. In cells with high 
membrane potential, the dye would form aggregates, resulting in a red shift in 
emission spectrum. However, in cells with low potential, the dye will be in 
monomeric structure and emits in green. Using, the change in red/green ratio, 
we can assess the change in mitochondrial membrane potential.  
In this final chapter, I first set up the live-imaging assay in neurons to 
measure changes in mitochondrial membrane potential. Upon validating this 
assay with known uncouplers, I tested the effects of various lipids. Since 
mitochondria uncoupling has been associated with mitophagy, I also 
determined if lanosterol has a role in autophagy. Using LC3 as a marker for 
autophagy, I quantified both the size and number of autophagic vacuoles 
(AVs) in primary ventral midbrain neurons upon MPP+/lanosterol treatment. 
 
 
Materials and Method: Assessing mitochondrial membrane potential and 
autophagy 
Live-cell confocal imaging and measurement of mitochondrial membrane 
potential 
Mitochondrial membrane potential was assessed using 5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide (JC-1) as 
described (White and Reynolds, 1996) with slight modifications. All live-
imaging experiments were conducted in cell medium, (37°C & 5% CO2) with 
a spinning disk confocal microscope, equipped with a Cool SNAP HQ2 CCD 
camera (Photometrics), a fully automated stage and built in autofocusing 
system (PFS, Nikon), and driven by Metamorph 7.6 (Universal Imaging). JC-1 
is excited at 488-nm, and its fluorescence emission was collected at 530 ± 10 
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nm (green) and 590 ± 17 nm (red), corresponding to peak fluorescence from 
the monomer and aggregate signals, respectively. Mitochondrial membrane 
potential was measured by taking the red to green emission ratio.  
For ventral midbrain cultures (DIV7), cells were seeded at 50 
cells/mm2 in a glass-bottom labtek well. Cells were loaded with 1 µg/ml JC-1 
(Invitrogen) in culture medium, and were incubated for 30 min at 37°C, 
washed twice with HBSS, and imaged in conditioned culture medium.  Multi-
position time-lapse imaging of 10-15 randomly chosen fields was performed 
at 2-minute intervals over 40 minutes. At the end of the experiment, ventral 
midbrain cells were fixed on stage for 20 minutes with 4% PFA and stained 
for TH with a secondary antibody coupled to Alexafluro-568 (red) and DAPI. 
The retrospective staining of TH allowed for the identification of 
dopaminergic neurons, which were the only ones included in the analyses. 
Hippocampal cultures were plated at a higher density (300cells/mm2), and 
multi-position time-lapse imaging of 3-4 fields was performed at 30-seconds 
intervals for 20 minutes.  
For both types of cultures, the intensity of the JC-1 red-to-green ratio 
was measured in each frame, and the change in mitochondrial membrane 
potential was plotted as Δf/f0, where f0 is the average JC-1 red-to-green ratio 
over the first 10 frames before treatment. Decay curves were fitted to a mono-
exponential function, y = x0e-t/τ, using IGOR Pro 6.1. 
ATP extraction and measurement 
Two to three million hippocampal neurons were cultured for seven 
days and treated with various types of liposome (PC, Cholesterol, and 
lanosterol) for 24 hours. For each independent experiment, 2 technical 
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replicates were performed. Cells were washed three times with ice-cold PBS, 
then placed immediately with 200 µL of ice-cold 10% trichloroacetic acid 
(TCA) and kept on ice for 15 minutes. TCA supernatant were kept in -80°C 
for 1 week before measurement of ATP by luciferase assay. ATP 
Bioluminesence Assay Kit (Roche) was used to determine concentration of 
ATP.    
Quantification of autophagosome vacuoles (AV) 
Ventral midbrain cultures plated on 12-mm coverslips were treated for 
24 h with 10 µM MPP+ with or without 5 µM PC, 5 µM cholesterol, or 5 µM 
lanosterol. Cells were washed three times with PBS, then fixed with 4% 
paraformaldehyde for 20 min and permeabilized with 100µg/ml of digitonin 
for 10 minutes. Following permeabilization, cells were washed 3 times with 
PBS and stained with anti-TH (secondary: Alexa-fluor 488, green) and anti-
LC3 (1:100, mouse monoclonal, MBL cat no: 152-3A, secondary: Alexa-fluor 
555, red). To quantify AV in dopaminergic neurons, TH+ cell soma were 
imaged with a laser-scanning confocal microscope (LSM510, Carl Zeiss) with 
excitation and emission filters meeting the secondary Alexa-fluor antibody 
dye specifications. Images were taken using a 63X objective with the same 
laser power and gain. The 12-bit images were quantified using ImageJ 
(analyze particle drop-in). For each image, detected LC3 puncta were intensity 
thresholded (<1000) and gated for size (<15 pixel). For each condition, 40-60 
TH+ cells were assessed from three independent experiments.  
As a positive control for our method of evaluating AV, mouse 
embryonic fibroblast (MEFs) grown in serum or serum deprived were stained 
with LC3 and quantified according to the same parameters. As expected and 
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shown below (Fig 16), there is approximately a 25-fold increase in AV upon 
serum starvation.  
Quantification of mitophagy in axons 
E18.5 hippocampal neurons were electroporated using the Amaxa 
poration system (Lonza) with MitoRed construct (Clonetech, cat no: PT-3633-
5). Cells were then plated in microfluidic chambers (Xona microfluidics), 
which allowed for physical separation of axons and cell somas. At DIV7, 
neurons were treated with 5 µM PC, 5 µM cholesterol, 5 µM lanosterol, or 
200 nM of rapamycin (positive control) for 24 hours. Cells were then fixed 
with 4% paraformaldehyde for 20 min and permeabilized with 100µg/ml of 
digitonin for 10 minutes. Following permeabilization, cells were washed 3 
times with PBS, and stained with anti-LC3 (secondary: Alexa-fluor 488, 
green). To quantify mitophagy, the percentage of MitoRed and LC3 positive 
mitochondria were plotted as a percentage to total MitoRed positive 
mitochondria using the Metamorph 7.6 colocalization drop-in. For each 
condition, images of 40-50 axons were taken from three independent 
experiments.   
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Figure 16: (A) Confocal images of mouse embryonic fibroblast (MEF) stained with LC3. Left 
panel corresponds to cells grown in 10% FBS, right panel corresponds to cells serum starved 
for 4 hours. Scale bar represents 10 µm. (B) Quantification of autophagosome vacuoles total 
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Results: Live-imaging analysis of neuronal mitochondrial membrane potential 
Even though JC-1 is well-established dye in the literature, the 
concentration used for each cell type differs. The amount loaded in neurons 
was published to be 2 µg/ml. However, in our study, we found that this 
concentration is too high, causing most of the dye to appear in aggregate 
forms. The final concentration used in our study is 0.5 µg/ml. As a positive 
control to our live imaging assay, we treated neurons stained with JC-1 with 
protonophore m-chlorophenylhydrazone (CCCP), an uncoupler of 
mitochondrial oxidative phosphorylation (Fig 17A). As expected, treatment of 
neurons with 200 nM of CCCP induced a sharp and immediate drop of 
mitochondrial membrane potential. As shown, ΔΨ was altered by 25% while 
there is no change in ΔΨ for control, non-treated neurons (Fig 17B). Under 
these same experimental conditions, exogenous lanosterol reduced the ΔΨ by 
~20% over 15 min, whereas PC and cholesterol had no significant effect (Fig 
18).  
These experiments were repeated again in ventral midbrain cultures. 
As these cultures were grown at a lower density than the hippocampal culture, 
we were only able to image at 2 minutes per frame over 40 minutes in order to 
capture multiple fields. At the end of the experiments, dopaminergic neurons 
were identified by posteriori staining for TH. Similar to results shown in 
hippocamapal neurons, lanosterol induces a similar (~20%) reduction in 
membrane potential in dopaminergic neurons (Fig 19). 
Since MPP+ uptake depends on ATP levels (Ramsay and Singer, 
1986), it is possible that the addition of lanosterol causes mitochondrial 
depolarization, and subsequently ATP depletion. This would inhibit MPP+ 
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uptake in the mitochondria. To determine if lanosterol alters ATP levels, we 
measured levels of ATP in neurons treated with PC, cholesterol, or lanosterol. 
We did not see any significant changes in the levels of ATP across all 
treatment conditions (Fig 20), indicating that lanosterol is unlikely to inhibit 
MPP+ uptake. Thus, one mechanism by which lanosterol could mediate 
neuroprotection is through the uncoupling of mitochondria.  
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Figure 17: Mitochondrial membrane potential assay  
 
 
Figure 17: Graphical representations of the change in mitochondrial membrane potential 
versus time in (A) the positive control using 200 nM CCCP and (B) the negative control, 
which received no treatment. Error bars represent SEM (n > 30) from more than three 
independent experiments.  
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Figure 18: Lanosterol induces mild uncoupling in neuronal mitochondria 
 
 
Figure 18: Live imaging of hippocampal neurons was performed after cells were loaded with 
JC-1. The change in mitochondrial membrane potential is measured as the ratio of intensity in 
the emissions channel at 594 (red) to 510 nm (green). Images shown are at the start of the 
experiment (time = 0 s), immediately before lipid addition (time = 240 s), and at the end of the 
experiment (time = 1470 s). Scale bar represents 10 µm. Neurons were treated with (A) 5 µM 
PC, (B) 5 µM cholesterol, or (C) 5 µM lanosterol. (D) Plot of JC-1 red to green ratio, Δf/f0, 
versus time for each condition.  
Lynette Lim Lanosterol is a survival factor for dopaminergic neruons 
Page 74 
 




Figure 19: Live imaging of JC-1 loaded neuronal cultures. (A) Images of control and lanosterol-
treated ventral midbrain cultures at the start of the experiment (time = 0 min, left panel) and the 
end of the experiment (time = 40 mins, middle panel). Right panels represent posteriori staining 
of TH for identification of dopaminergic neurons. White boxes represent magnified TH+ 
neurons. Scale bar represents 100 µm in main figure and 10 µm in magnified box. (B) Plot of 
Δf/f0 versus time for dopaminergic neurons, n > 10 for each condition from three independent 
experiments. In both types of cultures, lanosterol induces about 20% decrease in mitochondrial 
membrane potential.  
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Figure 20: (A) Bio–luminescence intensities for known ATP levels were fitted to a linear 
equation to obtain a standard curve. (B) ATP levels measure in neurons treated with various 
lipids conditions showed no significant changes in all four conditions. Error bars represent 
SEM over three independent experiments. 
 
Lanosterol increases autophagy in dopaminergic neurons.  
Previous studies have shown that the loss of mitochondrial membrane 
potential can initiate the autophagic degradation of damaged mitochondria 
(Matsuda et al., 2010; Narendra et al., 2008). Gene linked to familial forms of 
PD, such as PINK and Parkin are thought to regulate this process, and PD-
associated Parkin mutations cause a decrease in mitophagy in mammalian cell 
lines (Geisler et al., 2010b). We thus asked if lanosterol mediates 
autophagosome formation in dopaminergic neurons. Using LC3 as a marker 
for autophagy, we quantified both the size and number of autophagic vacuoles 
(AVs) in primary ventral midbrain neurons upon MPP+/lanosterol treatment. 
Similar to other studies (Cherra et al., 2010), we found that addition of MPP+ 
in primary dopaminergic neurons increased the number of AVs by about 2.5 
folds (Fig 21). There is also about a 75% increase in the average size of AVs 
with MPP+ treatment. Remarkably, when neurons were exposed to lanosterol 
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alone, we observed a similar increase in AV size and number. Co-treatment of 
MPP+ and lanosterol led to an additive effect on autophagy, with significant 
increase in both the numbers and size of AVs, compared to MPP+ or 
lanosterol alone (Fig 21).   
Next, we addressed whether lanosterol has a specific effect on axonal 
mitophagy. In PD, axons of dopaminergic neurons progressively degenerate 
and “die back”, in a process which may be accelerated by mitochondrial 
dysfunction and involve mitophagy. For this, we grew hippocampal neurons in 
microfluidic chambers to segregate axons from neuronal cell bodies and 
dendrites (Park et al., 2009). Mitochondria were visualized by expression of 
the fluorescent reporter MitoRed and neurons were immunostained for 
endogeneous LC3. We found a small but significant increase in co-localization 
of MitoRed with LC3 (Fig 22) upon lanosterol treatment, suggesting an 
increase of axonal mitophagy. Taken together, these results suggest that the 
protective effects of lanosterol are mediated by mitochondria uncoupling, and 
subsequent clearance of damaged mitochondria.    
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Figure 21: Lanosterol and MPP+ increase the number of autophagosome 




Figure 21: (A) Confocal images of ventral midbrain neurons stained with TH (top panels), 
LC3 (middle panels) and AV quantification (ImageJ software output, bottom panels) with 
various treatment conditions indicated on the top.  Scale bar represents 10 µm. (B) Graphical 
plot showing the average number of AV identified per TH+ cells and the average size of AV 
in pixel area during treatment with various lipids and MPP+ co-treatment. For each condition, 
n > 40 TH+ cells from 3 independent experiments. Error bars represent SEM. ***p < 0.001 
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Figure 22: (A) Confocal images of 
hippocamal axons stained with LC3 
(top panels, green) and 
electroporated with MitoRed (middle 
panels, red). Bottom panel showing 
overlay of LC3 and MitoRed. White 
arrow represents co-localization of 
the two channels. Scale bar 
represents 20 µm. (B) Graphical plot 
of average percentage of 
mitochondria with LC3 positive 
stains. Error bars represent SEM. For 
each condition, n > 40 axons were 
assessed from 3 independent 
experiments. *p < 0.05 
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Conclusion and perspectives 
In this thesis, I have first used an in silico approach to map out possible 
pathways that could be of importance to dopaminergic neurons. Secondly, I 
performed a thorough characterization of sterol metabolites in the affected 
brain regions of an established animal model for PD, MPTP-treated mice, and 
found specific and substantial reductions of lanosterol. I cannot rule out the 
possibility that lanosterol is oxidized or metabolized to di-hydrolanosterol or 
other products in MPTP treated animals because I was unable to measure 
these oxidized metabolites.  
Other than this work, only a few other studies have biochemically 
addressed sterol biosynthesis and metabolism in neurons. For 
neurodegeneration models, in rats treated with 3-nitropropionic acid, 
lathosterol levels were lower in the striatum but higher in serum (Teunissen et 
al., 2001). Studies by Nieweg et al. (2009) showed that lanosterol levels are 
substantially higher in neurons than in astrocytes or oligodendrocytes (Nieweg 
et al., 2009), further suggesting that lanosterol plays an important role in 
neurons. 
Consistent with a role of lanosterol in PD pathogenesis, we observed 
an improved survival of MPP+-treated dopaminergic neurons upon exogenous 
addition of lanosterol (Chapter 2). Much of the subsequent work attempted to 
elucidate the mechanism by which lanosterol protects dopaminergic neurons. 
As such, one important observation is the striking relocalization of LSS from 
the ER to mitochondria in dopaminergic neurons following MPP+ treatment 
(Chapter 4), suggesting an increase of lanosterol synthesis in the 
mitochondria. Interestingly, recent lipidomic analysis of macrophages 
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stimulated with LipidA (a condition that leads to oxidative bursts) showed a 
pronounced increase in lanosterol levels in several intracellular compartments, 
including mitochondria (Andreyev et al., 2010), implicating that modulation 
of lanosterol metabolism may be part of a global cellular response to stress.  
If upregulation of lanosterol synthesis is part of a cellular defense 
mechanism, it is not clear why lanosterol levels drop in response to MPTP 
treatment. In this regard, it is interesting to note that two recent papers 
reported lowered lanosterol levels in the serum of patients with Alzheimer’s 
disease (Kolsch et al., 2011), and in fibroblasts challenged by virus infection 
(Blanc et al., 2011). One possible explanation for these seemingly 
contradicting results is that distinct types of stress differentially impact 
lanosterol metabolism. Perhaps, in some cases, the substantial decrease in 
lanosterol levels cannot be compensated by upregulation of lanosterol 
synthesis as part of the cell’s protective response. Alternatively, I cannot 
exclude the possibility that translocation of LSS to mitochondria in response 
to MPP+ is an epiphenomenon, which is not indicative of a cellular response 
to stress. 
These results, however, demonstrate that exogenous addition of 
lanosterol leads to mild uncoupling of mitochondria in dopaminergic and 
glutamatergic neurons, with no detectable impact on ATP levels (Chapter 5). 
The mitochondria uncoupling and protective effects of lanosterol are strikingly 
similar to those observed with low dose of the uncoupler, FCCP, which 
improves cellular survival in ischaemic preconditioning but has no significant 
impact on ATP levels (Brennan et al., 2006). In the context of PD, the 
mitochondrial uncoupling effect of lanosterol has important implications. For 
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example, Parkin is recruited to mitochondria via PINK1 upon membrane 
depolarization (Narendra et al., 2008), and regulates the clearance of damaged 
mitochondria by mitophagy in mammalian cell lines (Geisler et al., 2010a). In 
addition, the translocation of Parkin to mitochondria has etiological 
significance, as a number of disease-associated Parkin mutant proteins fail to 
translocate (Matsuda et al., 2010; Okatsu et al., 2010). Together, these data 
point to a role of mitochondrial uncoupling and autophagy in PD 
pathogenesis. In line with this model, our results reveal that lanosterol induces 
mitochondrial uncoupling (Fig 18, 19) and promotes autophagy (Fig 21, 22).  
To date, the evidence linking PD to impaired mitochondrial function is 
substantial, including (1) identification of (rare) PD-associated mutations that 
affect mitochondrial function, e.g., the putative kinase PINK1 (PARK6), 
which is targeted to mitochondria, the E3 ligase Parkin (PARK2), and DJ-1 
(PARK7); (2) similarities between PD and clinical symptoms that arise upon 
exposure to the neurotoxin MPTP, a complex I inhibitor; and (3) a significant 
decrease in complex I/II activity in platelets of patients with PD (Haas et al., 
1995). But exactly what aspects of mitochondria functions are impaired in PD 
has been an evolving answer throughout the last few decades for 
neurobiologists. 
While mitochondria are classically seen as the powerhouse of the cell 
by generation of ATP through the respiratory chain/oxidative phosphorylation 
(mitochondria bioenergetics), there are many other functions that are equally 
as important though less mentioned such as calcium buffering through ER-
Mito communication, quality control of mitochondria (mitophagy), and 
mitochondria trafficking (Schon and Przedborski, 2011). In the earlier days of 
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PD research, bioenergetics defects in PD and oxidative stress, caused by 
impaired electron chain transport, were the two most popular hypotheses and 
thought to be the cause of the disease. But the data supporting these has been 
refuted throughout years and currently, the role of mitochondria bioenergetic 
compromises are seen as a consequence rather than the cause of the disease 
(see recent review, (Schon and Przedborski, 2011). Thus, the present view is 
to focus on mitochondria biology in the context of PD as an integrative 
subcellular system, encompassing four major aspects: (1) mitochondria 
bioenergetics, (2) mito-ER interactions, (3) mitochondria quality control by 
mitophagy, fusion, of fission, and (4) mitochondria trafficking in a highly 
polarized cell (such as neurons). Under such a view, any alteration in 
mitochondria dynamics (aspects 2-4: interaction with ER, mitophagy, or 
trafficking) instead of bioenergetics, would have a greater importance in 
neurons due to their high morphological polarity compared to myocytes.  
Our results showed that a sterol biosynthetic enzyme, LSS, upon 
cellular stress, translocates from the ER to mitochondria, which could provide 
key connection between lipid and mitochondria dynamics of a dopaminergic 
neuron. Furthermore, exogenous addition of lanosterol leads to mild 
uncoupling. As shown in other studies, mitochondrial uncoupling is 
neuroprotective in various models, including MPTP-induced 
neurodegeneration (Andrews et al., 2005; Conti et al., 2005; Horvath et al., 
2003). While the mechanisms involved are still unclear, some studies have 
suggested that uncoupling reduces superoxide species, offering an explanation 
for improved neuronal survival in the MPTP model, since oxidative stress is 
thought to be the primary cause of cell death (Andrews et al., 2005; Conti et 
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al., 2005). In other studies, transient mitochondrial uncoupling is 
neuroprotective in glutamate-induced neurotoxicity, as it prevents uptake of 
calcium from the cytosol to mitochondria (Stout et al., 1998). Finally, a recent 
study showed that DJ-1, a gene involved in early onset PD, regulates the 
expression of two uncoupling proteins (UCP4 and UCP5) and controls 
oxidative stress in mitochondria of dopaminergic neurons in the substantia 
nigra (Guzman et al., 2010). While these studies cited above have identified 
different modulators by which a cell/neuron alters mitochondria membrane 
potential, they are in good agreement with my findings, whereby uncoupling 
mechanism proves to be a central regulator of cellular response to stress.  
Taking these concepts together and the data presented here, I thus 
propose the following model (Fig 23). It has been well known that 
dopaminergic neurons in the SNpc have high pacemaking activities in absence 
of any excitatory inputs (Grace and Onn, 1989). This is achieved at a high 
expense by increasing cytoslic Ca2+ levels via L-type Ca2+ channels. This high 
Ca2+ cytosolic flux also increases superoxides species in the mitochondria 
(Beal, 1998). To compensate for this, in SNpc dopaminergic neurons, there are 
a number of “buffering” mechanisms. For example, there are elevated levels 
of the cytosolic Ca2+ binding protein, Calbindin, compared to the 
dopaminergic neurons of VTA (Liang et al., 1996). Uncoupling mechanisms 
specifically in these neurons appear to be important to buffer oxidative stress 
generated by high Ca2+(Guzman et al., 2010). Thus in a disease or stress state, 
another way to increase a neuron’s buffering capacity could be by uncoupling 
via translocation of LSS from ER to mitochondria, allowing for a local 
increase of lanosterol. At the same time or as a consequence, there is also an 
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increase in autophagosome formation as mitophagy is highly linked to the 
mitochondrial membrane potential.  
In a theoretical pathogenic scenario like PD, if there is a compromise 
in this pathway, by either (1) lack of Ca2+ buffer, (2) lack of superoxide 
quencher, (3) lack of uncoupling ability,  (4) defects in autophagic initiation, 
(5) impaired mitophagy, or any the above combinations, one could speculate 
that a cell type with a higher basal “burden” of oxidative stress or cytoslic 
calcium would tend to be most vulnerable. This model, if correct, appears to 
be an attractive one as it integrates many main lines of evidence and 
hypotheses published in the PD literature, including oxidative stress, 
autophagy/ protein quality control, and mitochodria dysfunction.  However, 
clearly, this might very well be only a partial model as it does not address all 
the risk factors associated with PD. For example, there is no explanation to 
how ER stress or misfolded proteins could result in PD pathogensis. There are 
also genes involved in PD that appear to have no link to this model such as 
UCHL1 (Table 1).  
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Figure 23: (A) In a healthy state, pacemaking activities of SNpc dopaminergic neurons result in 
high cytosolic Ca2+ and superoxide. This can be ameliorated by endogenous uncoupling defense 
system. (B) Under cellular stress, where there is additional burden of superoxide species, LSS 
translocates from ER to mitochondria to increase local lanosterol level. Autophagy is also 
increased in this process. However, this might not be sufficient to prevent cell death. (C) In 
MPP+ and lanosterol treatment, exogenous lanosterol could increase uncoupling capacity as 
well as induce autophagy. This allows for additional cellular defense upon pathogenesis.  
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However, the proposed model is conceptually important. In 
considering PD, which is a multifactorial, adult on-set degenerative disease, 
one ought to evaluate the evidence in terms of an integrative pathway and 
identify associated risks factors. We ought to see misregulation in Ca2+ or 
autophagy not as individual causes but as collective components of risks in a 
disease state. Because in sporadic cases, where one could find no known 
mutations in these identified pathways, where do these risks factors come 
from?  
Perhaps, this is where lipid analysis (or lipidomics) could provide 
additional insights. For example, in any given disease state, the protein along 
with environmental risks could lead to a change in metabolites inventory of 
cells or tissues. This misregulation could thus be a key to the disease state. 
Among cellular metabolites, lipids in the brain represent one of the highest yet 
poorly understood classes. Thus, as shown in this work, by examining the 
sterol metabolism pathway, I have uncovered an additional component of this 
multi-factorial aetiology.      
In conclusion, this thesis reports that lanosterol is not only a precursor 
for cholesterol synthesis, but acts as a cellular survival factor. These findings 
provide a novel mechanism for lanosterol-mediated cellular survival by 
regulating the mitochondrial membrane potential. These results also tie in well 
with the current literature to elucidate PD pathogenesis. Finally, these findings 
have important relevance for lanosterol-mediated mitochondrial function, and 
they bring sterol lipid metabolism to the forefront of neurobiology and 
neurodegeneration research.   
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